

CITATION REPORT

List of articles citing

A Multiple Testing Procedure for Clinical Trials

DOI: 10.2307/2530245
Biometrics, 1979, 35, 549.

Source: <https://exaly.com/paper-pdf/14273904/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2253	The beta-blocker heart attack trial. 1982 , 14 Suppl 1, 3S-5S		
2252	A case report of data monitoring experience: the nocturnal oxygen therapy trial. 1982 , 3, 113-24		34
2251	An investigation of an excess incidence of heart disease. 1983 , 2, 477-84		
2250	β-Blocker Heart Attack Trial. 1983 , 25, 314-317		
2249	Comment on "Statistical inference from clinical trials: choosing the right P value". 1983 , 4, 13-7		6
2248	Planning multicenter clinical trials: a biostatistician's perspective. 1983 , 4, 53-64		13
2247	Statistical strategies for animal conservation. 1983 , 406, 20-31		6
2246	33 Nonparametric frequentist proposals for monitoring comparative survival studies. 1984 , 791-811		1
2245	Stopping guidelines vs stopping rules: a practitioner's point of view. 1984 , 13, 2395-2417		39
2244	An overview of sequential methods and their application in clinical trials. 1984 , 13, 2315-2338		26
2243	Biopharmaceutical applications of group sequential designs. 1984 , 13, 2419-2450		
2242	Incorporating scientific, ethical and economic considerations into the design of clinical trials in the pharmaceutical industry: a sequential approach. 1984 , 13, 2355-2368		20
2241	Design of phase I and II clinical trials in cancer: a statistician's view. 1984 , 2, 483-91		57
2240	Can early stopping procedures impact significantly on the efficiency of clinical trials without serious loss of information?. 1984 , 3, 445-54		2
2239	Clinical trials in the evaluation of antiarrhythmic drugs: design, drugs, and double-blind considerations. 1984 , 432, 103-7		
2238	Designs for group sequential tests. 1984 , 5, 348-61		281
2237	Statistical aspects of early termination in the beta-blocker heart attack trial. 1984 , 5, 362-72		94

2236	Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. 1984 , 5, 373-81	16
2235	Repeated confidence intervals for group sequential clinical trials. 1984 , 5, 33-45	115
2234	Monitoring long-term clinical trials for beneficial and adverse treatment effects. 1984 , 13, 2369-2394	10
2233	More flexible sequential and non-sequential designs in long-term clinical trial. 1984 , 13, 2339-2353	47
2232	Treatment allocation methods in clinical trials: a review. 1985 , 4, 129-44	111
2231	Interim analyses in clinical trials: classical vs. Bayesian approaches. 1985 , 4, 521-6	87
2230	The Application of Hunter's Inequality in Simultaneous Testing. 1985 , 27, 25-38	19
2229	Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. 1985 , 71, 963-71	192
2228	Early decision in clinical trials when the treatment differences are small. Experience of a controlled trial in head trauma. 1985 , 6, 280-8	63
2227	Patients and methods. 1985 , 56, G3-G9	11
2226	The futility index. An approach to the cost-effective termination of randomized clinical trials. 1985 , 78, 635-43	67
2225	Treatment of duodenal ulcer with enprostil, a prostaglandin E2 analogue. 1986 , 81, 64-8	28
2224	Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. 1986 , 314, 1547-52	1967
2223	Monitoring boundaries for adverse effects in long-term clinical trials. 1986 , 7, 1-7	18
2222	Confidence intervals following group sequential tests. 1986 , 7, 18-26	74
2221	Truncated group sequential test for clinical trials. 1986 , 4, 121-129	1
2220	A proposal for interpreting and reporting negative studies. 1986 , 5, 203-9	75
2219	A simulation study of three sequential methods for the comparison of two treatment groups when the response criterion is censored. 1986 , 5, 375-85	13

2218	A clinical trial with an interim analysis. 1986 , 5, 387-92	6
2217	Interim Analyses in Randomized Clinical Trials. 1986 , 20, 263-270	2
2216	Interim Analysis in Clinical Trials: The Role of the Likelihood Principle. 1987 , 41, 117-122	23
2215	Optimal restricted two-stage designs. 1987 , 8, 146-56	15
2214	Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease. 1987 , 8, 216-42	37
2213	p-value and power computations in multiple look trials. 1987 , 40, 23-30	7
2212	Interim analyses in clinical research. 1987 , 5, 469-77	7
2211	Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. 1987 , 317, 1237-45	3317
2210	Effects on overviews of early stopping rules for clinical trials. 1987 , 6, 361-9	19
2209	Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation. 1987 , 6, 667-78	3
2208	Practical aspects in data monitoring: a brief review. 1987 , 6, 753-60	67
2207	Early termination of clinical trials with prolonged observation of individual patients: a case study. 1987 , 6, 927-37	2
2206	Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. 1987 , 59, 1072-82	63
2205	A comparison of epinephrine and methoxamine for resuscitation from electromechanical dissociation in human beings. 1988 , 17, 443-9	40
2204	Optimal two-stage designs for clinical trials with binary response. 1988 , 7, 571-9	31
2203	Stopping rules and estimation problems in clinical trials. 1988 , 7, 1231-42	86
2202	Statistical considerations for performing multiple tests in a single experiment. 6. Testing accumulating data repeatedly over time. 1988 , 63, 1245-50	18
2201	EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL. 1988 , 331, 545-549	17

2200	Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. 1988 , 29, 249-53	43
2199	Healing and relapse of severe peptic esophagitis after treatment with omeprazole. 1988 , 95, 903-12	685
2198	Interim Analyses: The Repeated Confidence Interval Approach. 1989 , 51, 305-334	15
2197	Sequential Tests of Hypotheses in Consecutive Trials. 1989 , 31, 663-676	18
2196	Discussion of the Paper by Jennison and Turnbull. 1989 , 51, 334-361	
2195	Design of Group Sequential Clinical Trials with Multiple Endpoints. 1989 , 84, 775-779	4
2194	Rioprostil and ranitidine in the treatment of prepyloric gastric ulcer. A double-blind comparative trial. 1989 , 24, 368-72	2
2193	A US multicenter study of enprostil 35 micrograms twice daily for treatment of prepyloric, pyloric channel, and duodenal bulb ulcers. Enprostil Study Group. 1989 , 34, 1355-60	3
2192	Comparison of Bayesian with group sequential methods for monitoring clinical trials. 1989 , 10, 357-67	81
2191	Practical problems in interim analyses, with particular regard to estimation. 1989 , 10, 209S-221S	97
2190	Analyses of group sequential clinical trials. 1989 , 10, 222S-230S	4
2189	Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study. 1989 , 64, 27A-29A; discussion 41A-42A	1
2188	A sequential elimination procedure for choosing the best population(s) based on multiple testing. 1989 , 21, 245-252	8
2187	The impact that group sequential tests would have made on ECOG clinical trials. 1989 , 8, 505-16	28
2186	Group sequential procedures: calendar versus information time. 1989 , 8, 1191-8	130
2185	Inference and decision in clinical trials. 1989 , 42, 293-9	20
2184	Optimal two-stage designs for phase II clinical trials. 1989 , 10, 1-10	2912
2183	Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry. 1989 , 10, 57-70	22

2182	Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. 1989 , 1, 175-9	1294
2181	Fluorouracil Filtering Surgery Study one-year follow-up. The Fluorouracil Filtering Surgery Study Group. 1989 , 108, 625-35	388
2180	Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. 1990 , 66, 315-22	191
2179	A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. 1990 , 149, 416-23	63
2178	Sequential stopping rules in clinical trials. 1990 , 9, 595-600	9
2177	CTS: a clinical trials simulator. 1990 , 9, 787-801	15
2176	Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. 1990 , 9, 881-92; discussion 903-6	34
2175	Application of the triangular test to phase II cancer clinical trials. 1990 , 9, 907-17	37
2174	Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. 1990 , 9, 1081-90	41
2173	An improved approximation for calculation of confidence intervals after a sequential clinical trial. 1990 , 9, 1277-85	13
2172	Group sequential designs using a family of type I error probability spending functions. 1990 , 9, 1439-45	165
2171	Planning sequential clinical trials: A review. 1990 , 9, 47-56	3
2170	The double triangular test: a sequential test for the two-sided alternative with early stopping under the null hypothesis. 1990 , 9, 117-136	19
2169	Issues in Planning Interim Analyses. 1990 , 24, 361-370	3
2168	Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. 1990 , 323, 769-75	279
2167	Upper bounds for type I and type II error rates in conditional power calculations. 1990 , 19, 3571-3584	37
2166	Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. 1990 , 335, 427-431	243
2165	Statistical methods and determination of sample size in the Growth Failure in Children with Renal Diseases Study. 1990 , 116, S32-6	10

2164	A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. 1990 , 323, 940-5	971
2163	Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. 1990 , 322, 352-8	1854
2162	Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence. 1990 , 322, 364-9	431
2161	Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. 1990 , 323, 1781-8	830
2160	Ondansetron. 1991 , 338, 753-754	14
2159	Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. 1991 , 338, 862-6	56
2158	Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. 1991 , 3, 287-302	49
2157	Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. 1991 , 325, 1468-75	1796
2156	A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. 1991 , 325, 303-10	2304
2155	Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. 1991 , 640, 253-62	38
2154	Termination of the Department of Veterans Affairs Cooperative Study of steroid therapy for systemic sepsis. 1991 , 12, 395-407	3
2153	Operational aspects of terminating randomization in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. 1991 , 12, 277-92	9
2152	Four problems with group sequential methods. 1991 , 12, 340-4	1
2151	Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. 1991 , 12, 566-86	91
2150	Stopping Rules for Clinical Trials Implicitly Incorporating Safety Information. 1991 , 33, 817-827	1
2149	The lipid research clinics coronary primary prevention trial: Design, results, and implications. 1991 , 40, S69-S75	10
2148	The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications. 1991 , 40 Suppl 1, S69-75	21
2147	Monitoring a randomized clinical trial for futility: the north-Norwegian lidocaine intervention trial. 1991 , 10, 405-12	7

2146	Multiple testing in clinical trials. 1991 , 10, 871-89; discussion 889-90	190
2145	Interim analysis in clinical trials. 1991 , 10, 925-35; discussion 936-7	51
2144	Using provisional diagnoses in monitoring a clinical trial. 1991 , 10, 1341-8	2
2143	Stagewise, group sequential experimental designs for quantal responses. one-sample and two-sample comparisons. 1991 , 15, 129-33	26
2142	Sequential Comparison of Changes with Repeated Measurements Data. 1991 , 86, 757-762	54
2141	Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis. 1991 , 17, 1162-7	4
2140	A controlled study of inhaled pentamidine for primary prevention of <i>Pneumocystis carinii</i> pneumonia. 1991 , 324, 1079-83	150
2139	A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. 1991 , 324, 509-16	715
2138	Rank Tests Based on Censored Data and Their Sequential Analogues. 1991 , 11, 147-176	8
2137	Bayesian Methods in Phase III Trials. 1991 , 25, 345-368	10
2136	Chemotherapy and radiation therapy as compared with radiation therapy in stage III non-small-cell cancer. 1991 , 324, 1136-7	12
2135	A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. 1992 , 327, 1842-8	313
2134	Comparison of a two-stage and three-stage interim-analysis procedure. 1992 , 71, 3-14	1
2133	A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. 1992 , 326, 1182-6	310
2132	Randomized trial of thrombolysis versus heparin in unstable angina. 1992 , 86, 1407-14	45
2131	A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. 1992 , 326, 437-43	295
2130	Sequential Rank Tests with Repeated Measurements in Clinical Trials. 1992 , 87, 136-142	21
2129	Repeated confidence intervals and prediction intervals using stochastic curtailment. 1992 , 21, 351-368	6

2128	When to stop a clinical trial. 1992 , 305, 235-40	165
2127	High-dose epinephrine in adult cardiac arrest. 1992 , 327, 1045-50	308
2126	A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. 1992 , 326, 793-8	304
2125	Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. 1992 , 21, 2833-2853	160
2124	Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. 1992 , 326, 1593-8	1614
2123	Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction: a preliminary report from the Cincinnati Heart Project. 1992 , 123, 835-40	136
2122	Monitoring clinical trials with a conditional probability stopping rule. 1992 , 11, 659-72	33
2121	A decision-theoretic evaluation of early stopping rules. 1992 , 11, 673-83	7
2120	Withdrawal censoring and the sequential logrank procedure. 1992 , 11, 1359-66	
2119	Sample size determination for group sequential clinical trials with immediate response. 1992 , 11, 1391-9	53
2118	Study duration for group sequential clinical trials with censored survival data adjusting for stratification. 1992 , 11, 1477-88	12
2117	Basic design considerations for clinical trials in oncology. 1992 , 83, 547-58	5
2116	A sequential procedure for a phase II efficacy trial in hypercholesterolemia. 1992 , 13, 122-33	22
2115	The succession procedure for interim analysis: extensions for early acceptance of H_0 and for flexible times of analysis. 1993 , 12, 51-67	3
2114	The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases. 1993 , 12, 461-7; discussion 469	24
2113	Monitoring of clinical trials and interim analyses from a drug sponsor's point of view. 1993 , 12, 481-92	14
2112	Interim analyses, stopping rules and data monitoring in clinical trials in Europe. 1993 , 12, 509-20	23
2111	P-values after repeated significance testing: a simple approximation method. 1993 , 12, 675-84	2

2110	Sequential monitoring of clinical trials: the role of information and Brownian motion. 1993 , 12, 753-65	113
2109	Stopping guidelines for clinical trials with multiple treatments. 1993 , 12, 901-15	30
2108	Statistical and ethical issues in monitoring clinical trials. 1993 , 12, 1459-69; discussion 1471-5	56
2107	Discussion. 1993 , 12, 1513-1517	5
2106	Use of spending functions for occasional or continuous monitoring of data in clinical trials. 1993 , 12, 2219-31	22
2105	Robust tests in group sequential analysis: One- and two-sided hypotheses in the linear model. 1993 , 45, 159-171	4
2104	An introduction to the use of interim data analyses in clinical trials. 1993 , 22, 1463-9	21
2103	Monitoring of clinical trials: issues and recommendations. 1993 , 14, 183-97	120
2102	Fixing the number of events in large comparative trials with low event rates: a binomial approach. 1993 , 14, 198-208	27
2101	A computer program for designing clinical trials with arbitrary survival curves and group sequential testing. 1993 , 14, 109-22	16
2100	Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. 1993 , 14, 6-18	8
2099	Exact repeated confidence intervals for Bernoulli parameters in a group sequential clinical trial. 1993 , 14, 19-29	13
2098	Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). 1993 , 14, 308-24	53
2097	An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 1993 , 329, 673-82	2979
2096	Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. 1993 , 329, 1213-8	425
2095	Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. 1993 , 342, 759-766	356
2094	A simple stopping rule for declaring treatment ineffectiveness in clinical trials. 1993 , 3, 13-22	
2093	Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. 1993 , 329, 1848-52	221

2092	Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. 1993 , 328, 1514-20	168
2091	The Use of Interim Analysis for Sample Size Adjustment. 1993 , 27, 753-760	42
2090	Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. 1993 , 37, 474-82	44
2089	Sample Size Reestimation for Triple Blind Clinical Trials. 1993 , 27, 761-764	17
2088	Issues in the Design of Long-Term Clinical Trials in Asthma. 1993 , 27, 793-803	1
2087	Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. 1993 , 88, 2045-8	244
2086	Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. 1993 , 12, 2-13	10
2085	Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. 1993 , 328, 1313-6	1385
2084	Outflow tract obstruction and failed mitral repair.. 1994 , 90, 1107-1108	14
2083	A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. 1994 , 90, 1765-73	753
2082	The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. 1994 , 89, 2892-907	55
2081	Sample Size Estimation When Time-to-Event is the Primary Endpoint. 1994 , 28, 865-877	7
2080	Information and information fractions for design and sequential monitoring of clinical trials. 1994 , 23, 403-420	44
2079	Three-stage designs for monitoring clinical trials. 1994 , 23, 1875-1893	
2078	A two-stage sequential design and analysis for comparing binomial rates with possibly random dropouts. 1994 , 23, 467-484	
2077	Group sequential analysis of a clinical trial with repeated measurements. 1994 , 23, 981-995	1
2076	Approximations in a group sequential test with unequal group sizes. 1994 , 23, 915-924	
2075	A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. 1994 , 331, 1181-7	124

2074	Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic Designs. 1994 , 89, 1528-1534	63
2073	Effect of omeprazole and sucralfate on prepyloric gastric ulcer. A double blind comparative trial and one year follow up. 1994 , 35, 837-40	4
2072	Multistage test procedure for testing Blackwelder's hypothesis of equivalence. 1994 , 4, 165-71	6
2071	A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. 1994 , 330, 382-6	88
2070	[Implementing ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity]. 1994 , 20, 319-28	7
2069	Group sequential testing in clinical trials with multivariate observations: a review. 1994 , 13, 101-11	29
2068	Use of surrogate information time for monitoring the effect of treatment on the change in a response variable in clinical trials. 1994 , 13, 945-53	1
2067	Interim analysis: the alpha spending function approach. 1994 , 13, 1341-52; discussion 1353-6	330
2066	Discussion of Interim analysis: The alpha spending approach 1994 , 13, 1353-1356	46
2065	Sequential methods based on the boundaries approach for the clinical comparison of survival times. 1994 , 13, 1357-68; discussion 1369-70	24
2064	The what, why and how of Bayesian clinical trials monitoring. 1994 , 13, 1371-83; discussion 1385-9	74
2063	Discussion of The what, why and how of bayesian clinical trials monitoring 1994 , 13, 1385-1389	10
2062	Some practical aspects of the interim monitoring of clinical trials. 1994 , 13, 1401-9	26
2061	Triangular test and randomized trials: practical problems in a small cell lung cancer trial. 1994 , 13, 1415-21	6
2060	Monitoring multi-armed trials. 1994 , 13, 1441-52	29
2059	A unified method for monitoring and analysing controlled trials. 1994 , 13, 1815-26	29
2058	Monitoring of a pilot toxicity study with two adverse outcomes. 1994 , 13, 2311-21	11
2057	Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter clinical trial. 1994 , 20, 618-625	51

2056	Multiple Testing for Detecting Efficient Dose Steps. 1994 , 36, 1-15	2
2055	A Group Sequential Method for one Standard Control and more than one Experimental Treatment. 1994 , 36, 515-529	
2054	Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. 1994 , 42, 19-35	163
2053	Problems of multiplicity in clinical trials. 1994 , 42, 209-221	12
2052	Data monitoring in complex clinical trials: which treatment is Better? 1994 , 42, 241-255	7
2051	An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives. 1994 , 15, 277-83	9
2050	Multistage decision problems. 1994 , 13, 329-349	4
2049	Data monitoring in clinical trials: the case for stochastic curtailment. 1994 , 47, 1033-42	18
2048	Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. Survanta Multidose Study Group. 1994 , 124, 962-7	30
2047	Reply. 1994 , 171, 1401-1410	33
2046	Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994 , 331, 1173-80	3081
2045	Effect of intrapartum epidural anesthesia on nulliparous labor: no answers yet. 1994 , 171, 1400, 1401-10	1
2044	Early stopping rules and long-term follow-up in phase III trials. 1994 , 10 Suppl 1, S151-9	6
2043	The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials. 1994 , 5, 171-83	44
2042	Comparison of sequential and fixed-sample designs in a controlled clinical trial with laparoscopic versus conventional cholecystectomy. 1994 , 29, 854-8	8
2041	The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. 1995 , 16, 408-21	55
2040	Antiarrhythmics Versus Implantable Defibrillators (AVID) Rationale, design, and methods. 1995 , 75, 470-475	117
2039	The U.K. Small Aneurysm Trial: design, methods and progress. The UK Small Aneurysm Trial participants. 1995 , 9, 42-8	88

2038	A Bayesian group sequential design for a multiple arm randomized clinical trial. 1995 , 14, 381-94	30
2037	A simulation study used to design the sequential monitoring plan for a clinical trial. 1995 , 14, 2227-37	14
2036	Use of the fast fourier transform algorithm in the calculation of the operating characteristics of group sequential clinical trials. 1995 , 20, 491-498	4
2035	SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests. 1995 , 46, 143-53	2
2034	Sequential testing with interval censored data *. 1995 , 51, 239-247	
2033	Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. 1995 , 333, 1301-7	6253
2032	Optimal two-sided group sequential tests. 1995 , 14, 273-286	30
2031	Group Sequential Monitoring of Clinical Trials with Multivariate Outcomes. 1995 , 29, 1563S-1582S	
2030	Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. 1995 , 332, 1671-7	401
2029	Interim Analyses: An FDA Reviewer's Experience and Perspective. 1995 , 29, 729-737	4
2028	Group Sequential Monitoring of Multi-Armed Clinical Trials. 1995 , 29, 705-713	4
2027	Tissue plasminogen activator for acute ischemic stroke. 1995 , 333, 1581-7	9677
2026	A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. 1995 , 173, 1578-84	81
2025	Statistical issues and analysis of mortality and morbidity randomized clinical trials in congestive heart failure. 1995 , 1, 303-9	
2024	Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. 1995 , 346, 459-61	141
2023	Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. 1996 , 335, 1107-14	944
2022	Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. 1996 , 348, 7-12	1115
2021	The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. 1996 , 334, 1349-55	3610

2020	An O'Brien-Fleming sequential trial for comparing three treatments. 1996 , 24, 1765	14
2019	Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. 1996 , 7, 815-20	26
2018	1 The design and analysis of clinical trials. 1996 , 1-29	4
2017	Efficient allocations in group sequential tests. 1996 , 25, 1769-1781	
2016	Controlled clinical trials in cancer research. 1996 , 35 Suppl 8, 27-33	1
2015	Penicillin prophylaxis in complicated wounds of hands and feet: a randomized, double-blind trial. 1996 , 27, 275-8	9
2014	Group B Streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin. 1996 , 175, 1036-42	31
2013	Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. 1996 , 17, 509-25	74
2012	Data monitoring committees and problems of lower-than-expected accrual or events rates. 1996 , 17, 526-35	18
2011	Selegiline and mortality in Parkinson's disease. 1996 , 40, 841-5	37
2010	A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. 1996 , 335, 1081-90	777
2009	Statistical Packages for Group Sequential Methods. 1996 , 50, 183-192	10
2008	A Step-by-Step Recommendation for Sample Size Adjustment in Clinical Trials. 1996 , 30, 957-960	
2007	Comparison of the spending function method and the Christmas tree correction for group sequential trials. 1996 , 6, 361-73	26
2006	Sequential type nonparametric tests for ordered bivariate alterenatives. 1996 , 15, 123-144	2
2005	Statistical Considerations for Multiplicity in Confirmatory Protocols. 1996 , 30, 523-534	85
2004	A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. 1996 , 335, 377-83	253
2003	A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. 1996 , 335, 384-91	265

2002	Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 1997 , 336, 1704-12	125
2001	A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 1997 , 337, 1576-83	2492
2000	A group sequential approach to crossover trials for average bioequivalence. 1997 , 7, 87-96	12
1999	Incorporation of a stopping criterion for futility into the design of a clinical trial with one interim analysis. 1997 , 26, 1011-1030	2
1998	A sequential trial of pain killers in arthritis: issues of multiple comparisons with control and of interval-censored survival data. 1997 , 7, 333-53	6
1997	Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. 1997 , 337, 1861-9	742
1996	Design principles and statistical considerations in periodontal clinical trials. 1997 , 2, 42-63	41
1995	Interim analyses and early termination of clinical trials. 1997 , 7, 533-43	7
1994	Group-Sequential Analysis Incorporating Covariate Information. 1997 , 92, 1330-1341	89
1993	A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. 1997 , 336, 1621-8	758
1992	Discussion of β -value adjustments for subgroup analyses 1997 , 7, 323-331	20
1991	Bias reduction via resampling for estimation following sequential tests. 1997 , 16, 249-267	10
1990	Group sequential χ^2 statistic for testing the difference of two mean vectors in clinical trials. 1997 , 26, 3015-3029	
1989	Application of boundary calculation methodologies to group sequential testing in general parametric models. 1997 , 26, 2173-2190	
1988	The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 1997 , 336, 912-8	679
1987	Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. 1997 , 350, 389-396	250
1986	Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. 1997 , 350, 681-6	507
1985	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. 1997 , 350, 757-64	2396

1984	Atrial Fibrillation Follow-Up Investigation of Rhythm Management—the AFFIRM Study Design. 1997 , 79, 1198-1202	239
1983	Discussion: On the role and analysis of secondary outcomes in clinical trials. 1997 , 18, 561-567	26
1982	Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). 1997 , 18, 358-77	54
1981	An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). 1997 , 18, 420-30	8
1980	Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. 1997 , 18, 580-93; discussion 661-6	308
1979	A better stopping rule for conventional statistical tests. 1998 , 30, 690-697	27
1978	Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. 1998 , 19, 61-109	2064
1977	Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) patch trial. 1998 , 19, 1-14	10
1976	Cooperative studies in health services research in the Department of Veterans Affairs. 1998 , 19, 134-48	11
1975	Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. 1998 , 19, 314-35	155
1974	Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. 1998 , 19, 370-90	75
1973	Design of a Clinical Trial for the Assessment of Cardioversion Using Transesophageal Echocardiography (The ACUTE Multicenter Study) 11This study was supported in part by grants from the American Medical Association Education and Research Foundation, Chicago, Illinois; and American Society of Echocardiography, Durham, North Carolina. 1998 , 31, 877-888	30
1972	Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. 1998 , 82, 25H-30H	70
1971	The Ontario Prehospital Advanced Life Support (OPALS) Study: rationale and methodology for cardiac arrest patients. 1998 , 32, 180-90	61
1970	Exact calculations for the repeated many-one test. 1998 , 27, 389-399	
1969	Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. 1998 , 351, 543-9	439
1968	Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. 1998 , 351, 233-241	699
1967	Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. 1998 , 352, 1649-1655	923

1966	A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 1998 , 133, 500-8	99
1965	Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research Investigators. 1998 , 31, 312-20	21
1964	Group sequential designs using both type I and type II error probability spending functions. 1998 , 27, 1323-1339	27
1963	Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. 1998 , 339, 1979-84	1085
1962	Monitoring women at risk for preterm labor. 1998 , 338, 15-9	169
1961	A comparison of rectal diazepam gel and placebo for acute repetitive seizures. 1998 , 338, 1869-75	213
1960	Interim analyses of survival data in cancer clinical trials. 1998 , 37, 645-50	2
1959	Benefits and risks of screening mammography for women in their forties: a statistical appraisal. 1998 , 90, 1431-9	69
1958	Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. 1998 , 338, 1785-92	615
1957	Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group. 1998 , 338, 493-8	81
1956	Some issues in stochastic curtailing. 1998 , 27, 1409-1418	3
1955	Repeated significance tests on accumulating data of repairable systems. 1998 , 27, 1181-1200	1
1954	Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. 1998 , 339, 1649-56	506
1953	A boundary crossing probability for the Bessel process. 1998 , 30, 807-830	3
1952	A boundary crossing probability for the Bessel process. 1998 , 30, 807-830	3
1951	A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. 1998 , 19, 339-49	52
1950	Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. 1998 , 42, 1139-45	45
1949	A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. 1999 , 104, 91-9	136

1948	Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. 1999 , 17, 3299-306	240
1947	On group sequential tests based on robust location and scale estimators in the two-sample problem. 1999 , 14, 339-353	
1946	Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. 1999 , 160, 1238-43	24
1945	Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. 1999 , 100, 2312-8	780
1944	Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. 1999 , 91, 66-72	793
1943	Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective. 1999 , 33, 165-176	10
1942	Group Sequential Monitoring of Multi-Armed Clinical Trials. 1999 , 33, 479-486	1
1941	Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. 1999 , 341, 312-8	303
1940	Sequential Designs for Monitoring Two Endpoints in a Clinical Trial. 1999 , 33, 417-426	14
1939	Group sequential checking of the proportional hazards assumption based on a time-dependent covariate. 1999 , 28, 1931-1943	1
1938	Statistical methods for monitoring clinical trials. 1999 , 9, 599-615	5
1937	Group sequential procedures for repeated events data with frailty. 1999 , 9, 379-99	8
1936	Advances in clinical trials in the twentieth century. 1999 , 20, 109-24	17
1935	Multiple comparisons in interim analysis. 1999 , 82, 5-23	14
1934	Procedures for testing multiple endpoints in clinical trials: An overview. 1999 , 82, 69-81	25
1933	A one-sided confidence set hidden under a two-sided sequential test of a normal mean. 1999 , 41, 435-438	0
1932	Estimation following group sequential tests with repeated measurements data. 1999 , 32, 69-77	5
1931	A group sequential test for survival trials: an alternative to rank-based procedures. <i>Biometrics</i> , 1999 , 55, 277-83	1.8 11

1930	Modification of sample size in group sequential clinical trials. <i>Biometrics</i> , 1999 , 55, 853-7	1.8	344
1929	A unifying family of group sequential test designs. <i>Biometrics</i> , 1999 , 55, 874-82	1.8	67
1928	Sequential methods for comparing years of life saved in the two-sample censored data problem. <i>Biometrics</i> , 1999 , 55, 1085-92	1.8	15
1927	Closed testing procedures for group sequential clinical trials with multiple endpoints. <i>Biometrics</i> , 1999 , 55, 1188-92	1.8	52
1926	Adaptive sample size calculations in group sequential trials. <i>Biometrics</i> , 1999 , 55, 1286-90	1.8	396
1925	Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. 1999 , 55, 51-9		35
1924	[Monitoring of clinical trials. Methodology, interim analyses, and end results]. 1999 , 94, 712-7		
1923	Data monitoring committees and interim monitoring guidelines. 1999 , 20, 395-407		51
1922	Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses. 1999 , 20, 423-38		19
1921	Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). 1999 , 20, 493-510		176
1920	The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. 1999 , 20, 573-600		391
1919	Interim analyses with delayed observations in clinical trials. 1999 , 18, 1297-306		2
1918	Combining mortality and longitudinal measures in clinical trials. 1999 , 18, 1341-54		163
1917	Longitudinal data analysis (repeated measures) in clinical trials. 1999 , 18, 1707-32		112
1916	Optimization of testing times and critical values in sequential equivalence testing. 1999 , 18, 1769-1788		11
1915	Group sequential analyses for the mean function of a repeated measure process. 1999 , 18, 2287-99		3
1914	The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. 1999 , 341, 709-17		6637
1913	A General Theory on Stochastic Curtailment for Censored Survival Data. 1999 , 94, 510-521		26

1912	Repeated significance tests on accumulating survival data. 1999 , 52, 1083-8	8
1911	Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. 1999 , 353, 773-80	615
1910	Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. 1999 , 354, 365-9	158
1909	The agonising negative trend in monitoring of clinical trials. 1999 , 354, 1983-8	111
1908	Statistical inference for self-designing clinical trials with a one-sided hypothesis. <i>Biometrics</i> , 1999 , 55, 190-7	1.8 112
1907	SACRAL NERVE STIMULATION FOR TREATMENT OF REFRACTORY URINARY URGE INCONTINENCE. 1999 , 162, 352-357	340
1906	The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. 1999 , 341, 1789-94	1184
1905	Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. 1999 , 340, 177-83	415
1904	Conditional estimation following a group sequential clinical trial. 1999 , 28, 1617-1634	21
1903	A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. 1999 , 341, 1882-90	1938
1902	Individually randomized intervention trials for disease prevention and control. 1999 , 8, 287-309	12
1901	Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. 2000 , 18, 136-47	1130
1900	An overview of group sequential methods in longitudinal clinical trials. 2000 , 9, 497-515	15
1899	Effects of 4 Hand-Drying Methods for Removing Bacteria From Washed Hands: A Randomized Trial. 2000 , 75, 705-708	30
1898	A Shift Algorithm for Exact Computation in Sequential Tests with Binary Outcome. 2000 , 42, 189-196	2
1897	Sample size calculation for planning group sequential longitudinal trials. 2000 , 19, 205-20	9
1896	Formal approaches to safety monitoring of clinical trials in life-threatening conditions. 2000 , 19, 2899-917	27
1895	A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05). 2000 , 46, 975-81	40

1894	A homogeneity test in overviews with group sequentially monitored clinical trials. <i>Biometrics</i> , 2000 , 56, 134-8	1.8	1
1893	Testing secondary hypotheses following sequential clinical trials. <i>Biometrics</i> , 2000 , 56, 640-4	1.8	12
1892	Survival analysis in clinical trials: past developments and future directions. <i>Biometrics</i> , 2000 , 56, 971-83	1.8	68
1891	Nonparametric rank-based methods for group sequential monitoring of paired censored survival data. <i>Biometrics</i> , 2000 , 56, 984-90	1.8	14
1890	The effect of hypotensive anesthesia on blood loss and operative time during Le Fort I osteotomies. 2000 , 58, 834-9; discussion 840		62
1889	Computations for group sequential boundaries using the Lan-DeMets spending function method. 2000 , 21, 190-207		98
1888	Statistical power for a long-term survival trial with a time-dependent treatment effect. 2000 , 21, 561-73		6
1887	Design and implementation of a controlled trial of pediatric endotracheal intubation in the out-of-hospital setting. 2000 , 36, 356-65		31
1886	Basic concepts of group sequential and adaptive group sequential test procedures. 2000 , 41, 253-279		22
1885	Interim Monitoring in Clinical Trials: Its Necessity. 2000 , 21, S1-S25		
1884	Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. 2000 , 18, 623-31		497
1883	Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. 2000 , 18, 2972-80		237
1882	18 Statistical perspectives in clinical epidemiology. 2000 , 18, 519-543		
1881	Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study. 2000 , 18, 418-24		15
1880	Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. 2000 , 342, 1069-76		383
1879	Point estimation after early stopping in a repeated measures trial. 2000 , 29, 399-417		1
1878	The Randomized Clinical Trial. 2000 , 95, 312-315		14
1877	Experimental Design in Clinical Trials. 2000 , 17, 285-344		1

1876	Alternative Derivations of a Rule for Early Stopping in Favor of H 0. 2000 , 54, 35-39	7
1875	Procedure for determining sample size at each stage in group sequential test. 2000 , 29, 987-1000	
1874	Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. 2000 , 101, 758-64	79
1873	Rationale and design of the Magnesium in Coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction. 2000 , 139, 10-14	25
1872	Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. 2000 , 140, 727-50	142
1871	Design and organization of the cilostazol stroke prevention study. 2000 , 9, 36-44	5
1870	The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. 2000 , 36, 994-1001	22
1869	Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 2000 , 355, 1582-7	1486
1868	Therapeutic studies. 2000 , 14, 849-76, ix	5
1867	Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. 2000 , 342, 1301-8	11655
1866	9 Non-parametrics in bioenvironmental and public health statistics. 2000 , 247-324	1
1865	Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses. 2000 , 29, 923-940	17
1864	SACRAL NEUROMODULATION IN THE TREATMENT OF URGENCY-FREQUENCY SYMPTOMS: A MULTICENTER STUDY ON EFFICACY AND SAFETY. 2000 , 163, 1849-1854	283
1863	Effects of 4 hand-drying methods for removing bacteria from washed hands: a randomized trial. 2000 , 75, 705-8	37
1862	Quality control of oncology clinical trials. 2000 , 14, 953-71, x	7
1861	Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. 2001 , 2, 210-5	30
1860	Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. 2001 , 32, 36-43	60
1859	Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. 2001 , 18, 151-64	115

1858	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. 2001 , 345, 861-9		5467
1857	Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. <i>Biometrics</i> , 2001 , 57, 886-91	1.8	258
1856	Making changes in clinical trials. 2001 , 141, 295-300		1
1855	Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. 2001 , 141, 528-35		95
1854	Optimized group sequential study designs for tests of genetic linkage and association in complex diseases. 2001 , 69, 590-600		14
1853	Adjusting for multiple testing--when and how?. 2001 , 54, 343-9		1692
1852	The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. 2001 , 37, 23-31		87
1851	Monitoring of large randomised clinical trials: a new approach with Bayesian methods. 2001 , 358, 375-81		61
1850	Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. 2001 , 165, 15-9		263
1849	Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. 2001 , 2, 77-87		74
1848	Effect of carvedilol on survival in severe chronic heart failure. 2001 , 344, 1651-8		2438
1847	Preventing recurrent upper gastrointestinal bleeding in patients with <i>Helicobacter pylori</i> infection who are taking low-dose aspirin or naproxen. 2001 , 344, 967-73		480
1846	BAYES DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL TRIALS. 2001 , 30, 1381-1394		2
1845	Clinical trials in lymphoma. 2001 , 55-67		
1844	Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. 2001 , 19, 2114-22		234
1843	Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. 2001 , 19, 2413-21		72
1842	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. 2001 , 29, 765-9		193
1841	Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). 2001 , 12, 1231-8		86

1840	Taxanes in the adjuvant treatment of breast cancer: why not yet?. 2001 , 88-95		26
1839	On group sequential tests for data in unequally sized groups and with unknown variance. 2001 , 96, 263-288		8
1838	Interim analyses and sequential designs in phase III studies. 2001 , 51, 394-9		28
1837	Use of the equivalence approach in reproductive health clinical trials. 2001 , 20, 3571-7		37
1836	Sample size calculations for the two-sample problem using the multiplicative intensity model. 2001 , 20, 557-79		18
1835	Optimal two-stage designs for clinical trials based on safety and efficacy. 2001 , 20, 1023-32		20
1834	Theory and practice in medical statistics. 2001 , 20, 2537-48		9
1833	Independent data monitoring committees: rationale, operations and controversies. 2001 , 20, 2573-83		22
1832	Sample size recalculation using conditional power. 2001 , 20, 2645-60		100
1831	Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. 2001 , 20, 1903-12		67
1830	Predicting analysis times in randomized clinical trials. 2001 , 20, 2055-63		30
1829	Group Sequential Methods with Applications to Clinical Trials. Christopher Jennison and Bruce W. Turnbull, CRC/Chapman & Hall, U.K., 2000. No. of pages: xviii +390. Price: £ 39.00. ISBN 0-849-30316-8. 2001 , 20, 2210-2211		
1828	Monitoring a clinical trial with multiple hypotheses concerning the treatment effect on a single primary endpoint. 2001 , 20, 2801-12; discussion 2813-4		11
1827	Interim monitoring of clinical trials based on long-term binary endpoints. 2001 , 20, 177-92		23
1826	Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. 2001 , 7, 369-74		3
1825	Estimation of a secondary parameter in a group sequential clinical trial. <i>Biometrics</i> , 2001 , 57, 589-97	1.8	2
1824	Monitoring clinical trials with multiple arms. <i>Biometrics</i> , 2001 , 57, 892-8	1.8	26
1823	A simple algorithm for designing group sequential clinical trials. <i>Biometrics</i> , 2001 , 57, 972-4	1.8	13

1822	A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. 2001 , 27, 269-78	7
1821	A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. 2001 , 28, 447-54	3
1820	Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2001 , 22, 29-41	22
1819	The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. 2001 , 22, 176-90	27
1818	Comparison of the two-sided single triangular test to the double triangular test. 2001 , 22, 503-14	17
1817	The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. 2001 , 4, 165-172	22
1816	A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. 2001 , 345, 631-7	634
1815	SAMPLE SIZES FOR BATCH ACCEPTANCE FROM SINGLE- AND MULTISTAGE DESIGNS USING TWO-SIDED NORMAL TOLERANCE INTERVALS WITH SPECIFIED CONTENT. 2001 , 11, 335-346	11
1814	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. 2001 , 93, 605-18	267
1813	Flexible Sample Size Considerations Using Information-Based Interim Monitoring. 2001 , 35, 1095-1112	60
1812	Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. 2001 , 345, 79-84	348
1811	Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. 2001 , 93, 597-604	220
1810	Flexible Interim Analyses in Clinical Trials Using Multistage Adaptive Test Designs. 2001 , 35, 1131-1146	20
1809	A clinical trial of estrogen-replacement therapy after ischemic stroke. 2001 , 345, 1243-9	744
1808	BIOPHARMACEUTICAL STATISTICS IN A PHARMACEUTICAL REGULATED ENVIRONMENT: PAST, PRESENT, AND FUTURE. 2001 , 11, 347-372	4
1807	A CASE STUDY OF THE EFFECT OF COVARIATE ADJUSTMENT IN A SEQUENTIAL SURVIVAL CLINICAL TRIAL. 2001 , 11, 297-311	1
1806	Sample Size Reestimation in Clinical Trials. 2001 , 35, 1409-1422	13
1805	Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 2002 , 346, 2033-8	480

1804	A comparison of rate control and rhythm control in patients with atrial fibrillation. 2002 , 347, 1825-33	3099
1803	Optimal two-stage designs for single arm phase II cancer trials. 2002 , 12, 39-51	56
1802	Confidence Intervals Following Group Sequential Tests in Clinical Trails with Multivariate Observations. 2002 , 72, 247-259	1
1801	Immediate repair compared with surveillance of small abdominal aortic aneurysms. 2002 , 346, 1437-44	846
1800	A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. 2002 , 165, 1526-30	64
1799	The view of The International Menopause Society on the Women's Health Initiative. 2002 , 5, 211-216	22
1798	Randomized discontinuation design: application to cytostatic antineoplastic agents. 2002 , 20, 4478-84	177
1797	Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. 2002 , 20, 2267-76	559
1796	Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. 2002 , 20, 2559-66	96
1795	Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?. 2002 , 11, 381-402	30
1794	A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. 2002 , 73, 1904-9	83
1793	Perspectives on the Women's Health Initiative Trial of Hormone Replacement Therapy. 2002 , 100, 1344-1353	1
1792	Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. 2002 , 30, 1-6	327
1791	The design of randomized clinical trials in critically ill patients. 2002 , 121, 1290-300	76
1790	Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 2002 , 346, 1854-62	723
1789	SEQUENTIAL METHODS IN CLINICAL TRIALS*. 2002 , 21, 285-308	2
1788	CONDITIONAL PROBABILITY OF SIGNIFICANCE FOR EARLY STOPPING IN FAVOR OF H 0. 2002 , 21, 145-160	2
1787	The truth is out there: a guide to the pitfalls of interpreting evidence-based medicine in studies of human reproduction. 2002 , 77, 223-8	11

1786	The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. 2002 , 78, 951-6	35
1785	Randomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: is local tamponade enough?. 2002 , 55, 6-10	33
1784	Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. 2002 , 346, 92-8	4300
1783	Effect of dialysis dose and membrane flux in maintenance hemodialysis. 2002 , 347, 2010-9	1412
1782	Recursive Combination Tests. 2002 , 97, 236-244	174
1781	ADAPTIVE GROUP SEQUENTIAL PROCEDURES FOR MULTIPLE COMPARISON OF TREATMENTS. 2002 , 31, 781-793	
1780	REPEATED SIGNIFICANCE TESTS IN FREQUENCY AND TIME DOMAINS*. 2002 , 21, 249-283	1
1779	Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. 2002 , 360, 528-34	337
1778	Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. 2002 , 360, 1189-96	172
1777	Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics. 2002 , 143, 15-21	108
1776	Hyperbaric oxygen for acute carbon monoxide poisoning. 2002 , 347, 1057-67	633
1775	Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. 2002 , 4, 95-103	12
1774	The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. 2002 , 23, 198-220	74
1773	A comment on fertility monitoring. 2002 , 23, 355-66	44
1772	Designing complex group sequential survival trials. 2002 , 21, 1969-89	36
1771	Minimax two-stage-designs with applications to tissue banking case-control studies. 2002 , 21, 2479-93	5
1770	Role of the Data and Safety Monitoring Committee (DSMC). 2002 , 21, 2823-9	22
1769	TACT method for non-inferiority testing in active controlled trials. 2003 , 22, 227-38	31

1768	Group sequential monitoring of years of life saved with paired censored survival data. 2002 , 21, 177-89		2
1767	Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. 2002 , 21, 467-80		18
1766	Self-designing two-stage trials to minimize expected costs. <i>Biometrics</i> , 2002 , 58, 432-8	1.8	8
1765	Group sequential methods for an ordinal logistic random-effects model under misspecification. <i>Biometrics</i> , 2002 , 58, 569-75	1.8	5
1764	Seamlessly expanding a randomized phase II trial to phase III. <i>Biometrics</i> , 2002 , 58, 823-31	1.8	92
1763	P-value adjustment in sequential clinical trials. <i>Biometrics</i> , 2002 , 58, 1005-11	1.8	10
1762	WHI: Now that the dust has settled: a commentary. 2003 , 189, 621-6		19
1761	Interim analyses of data as they accumulate in laboratory experimentation. 2003 , 3, 15		12
1760	A model for the interim analysis process: a case study. 2003 , 24, 51-65		5
1759	Statistical issues related to early closure of STOP-ROP, a group-sequential trial. 2003 , 24, 28-38		3
1758	Stopping the active intervention: CARET. 2003 , 24, 39-50		27
1757	Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. 2003 , 24, 16-27		11
1756	The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. 2003 , 24, 442-61		32
1755	Estimation following group-sequential response-adaptive clinical trials. 2003 , 24, 523-43		5
1754	Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. 2003 , 24, 610-28		59 ^I
1753	A matter of life and death? The Heart Protection Study and protection of clinical trial participants. 2003 , 24, 501-5		5
1752	A group sequential, response-adaptive design for randomized clinical trials. 2003 , 24, 506-22		64
1751	Sequential methods and group sequential designs for comparative clinical trials. 2003 , 17, 505-16		27

1750	Lansoprazole reduces ulcer relapse after eradication of <i>Helicobacter pylori</i> in nonsteroidal anti-inflammatory drug users--a randomized trial. 2003 , 18, 829-36	41
1749	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. 2003 , 55, 299-306	8
1748	Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. 2003 , 22, 1787-805	26
1747	A comparison of group sequential methods for binary longitudinal data. 2003 , 22, 501-15	4
1746	Group sequential design for comparative diagnostic accuracy studies. 2003 , 22, 727-39	28
1745	Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. 2003 , 22, 2239-56	109
1744	Issues in designing flexible trials. 2003 , 22, 953-69	88
1743	Over-ruling a group sequential boundary--a stopping rule versus a guideline. 2003 , 22, 3347-55	12
1742	Sample size re-estimation in group-sequential response-adaptive clinical trials. 2003 , 22, 3843-57	13
1741	Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. 2003 , 17, 1529-37	64
1740	Sequential tests for noninferiority and superiority. <i>Biometrics</i> , 2003 , 59, 106-14	1.8 31
1739	Incorporating data received after a sequential trial has stopped into the final analysis: implementation and comparison of methods. <i>Biometrics</i> , 2003 , 59, 701-9	1.8 8
1738	Flexible implementations of group sequential stopping rules using constrained boundaries. <i>Biometrics</i> , 2003 , 59, 770-7	1.8 26
1737	Monitoring the ERSPC trial. 2003 , 92 Suppl 2, 112-4	11
1736	Menopausal hormone therapy: a paradigm shift?. 2003 , 80, 494-5	1
1735	Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. 2003 , 42, 20-9	216
1734	Emboli capture using the Embol-X intraaortic filter in cardiac surgery: a multicentered randomized trial of 1,289 patients. 2003 , 76, 508-15; discussion 515	71
1733	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). 2003 , 362, 782-8	1630

1732	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. 2003 , 362, 859-68	396
1731	Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. 2003 , 95, 362-72	673
1730	A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. 2003 , 170, 810-5	208
1729	A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. 2003 , 349, 427-34	2332
1728	An Efficient Allocation in Group Sequential Tests for the Linear Mixed Effects Model. 2003 , 32, 585-599	1
1727	International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. 2003 , 95, 125-32	203
1726	Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. 2003 , 21, 3909-17	303
1725	Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. 2003 , 167, 841-9	257
1724	Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). 2003 , 14, S154-65	73
1723	Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. 2003 , 21, 607-14	389
1722	Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. 2003 , 21, 3296-302	320
1721	A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. 2003 , 36, 1221-8	410
1720	Data-driven analysis strategies for proportion studies in adaptive group sequential test designs. 2003 , 13, 585-603	9
1719	An adaptive approach to implementing bivariate group sequential clinical trial designs. 2003 , 13, 605-19	11
1718	Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. 2003 , 289, 217-22	277
1717	A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. 2003 , 14, 291-7	35
1716	Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. 2003 , 14, 589-94	33
1715	Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. 2003 , 14, 595-600	36

1714	A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. 2003 , 23, 582-94	70
1713	Conduct of Stroke-Related Clinical Trials. 2004 , 1187-1207	0
1712	Randomised controlled trial of health assessments for older Australian veterans and war widows. 2004 , 181, 186-90	45
1711	Bayesian methods to improve sample size approximations. 2004 , 383, 406-27	4
1710	Adjuvant chemotherapy for lung cancer. 2004 , 350, 1681-3; author reply 1681-3	5
1709	Data safety and monitoring boards. 2004 , 350, 1143-7	79
1708	Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. 2004 , 351, 217-28	364
1707	Conditional bias of point estimates following a group sequential test. 2004 , 14, 505-30	23
1706	Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach. 2004 , 14, 791-801	0
1705	The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. 2004 , 1, 91-107	41
1704	CRITICAL REVIEW OF THE ARMITAGE AND BROSS SEQUENTIAL PROCEDURES IN CLINICAL REHABILITATION TRIALS. 2004 , 08, 181-193	
1703	Peripherally inserted central catheters: a randomized, controlled, prospective trial in pediatric surgical patients. 2004 , 99, 1038-1043	39
1702	Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. 2004 , 1, 48-59	37
1701	Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. 2004 , 22, 4665-73	205
1700	A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. 2004 , 15, 947-54	255
1699	Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. 2004 , 15, 1048-55	44
1698	Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome. 2004 , 351, 136-44	1006
1697	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. 2004 , 351, 971-7	766

1696	A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). 2004 , 5, 7-18		10
1695	Group sequential design for comparative diagnostic accuracy studies: implications and guidelines for practitioners. 2004 , 24, 525-33		12
1694	Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 2004 , 350, 1850-61		429
1693	Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 2004 , 22, 2635-42		130
1692	Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. 2004 , 1, 326-38		10
1691	Design and analysis of group sequential clinical trials with multiple primary endpoints. <i>Biometrics</i> , 2004 , 60, 134-45	1.8	30
1690	Optimal conditional error functions for the control of conditional power. <i>Biometrics</i> , 2004 , 60, 715-23	1.8	25
1689	Stopping clinical trials by design. 2004 , 3, 973-7		25
1688	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. 2004 , 91, 1996-2004		151
1687	Radiant versus right internal thoracic artery for myocardial revascularizationReply to the Editor. 2004 , 127, 892-893		
1686	The advantages and disadvantages of adaptive designs for clinical trials. 2004 , 9, 351-7		44
1685	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. 2004 , 25, 472-92		151
1684	Increasing the sample size when the unblinded interim result is promising. 2004 , 23, 1023-38		151
1683	Choice of alpha spending function and time points in clinical trials with one or two interim analyses. 2004 , 3, 193-203		5
1682	Stepwise likelihood ratio statistics in sequential studies. 2004 , 66, 401-409		4
1681	The PAV trial: does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomised controlled trial [ISRCTN24141277]. 2004 , 5, 5		11
1680	Conditional Maximum Likelihood Estimation Following a Group Sequential Test. 2004 , 46, 760-768		15
1679	Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. 2004 , 19, 1215-21		60

- 1678 Some simple corrected confidence intervals following a sequential test. **2004**, 126, 189-205
- 1677 Group sequential design and analysis of clinical equivalence assessment for generic nonsystematic drug products. **2004**, 14, 359-73 16
- 1676 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. **2004**, 22, 23-30 1885
- 1675 Design of Group Sequential Clinical Trials with Ordinal Categorical Data Based on the Mann-Whitney-Wilcoxon Test. **2004**, 23, 413-426 6
- 1674 Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. **2004**, 350, 2140-50 4300
- 1673 Artificial and bioartificial support systems for liver failure. **2004**, CD003628 54
- 1672 Three-stage sequential statistical dissolution testing rules. **2004**, 14, 757-79 16
- 1671 Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. **2004**, 24, 137-47 7
- 1670 New developments in medical clinical trials. **2004**, 83 Spec No C, C18-24 12
- 1669 Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST). **2004**, 148, 386-92 18
- 1668 Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. **2004**, 60, 1-8 131
- 1667 Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. **2004**, 364, 1141-8 139
- 1666 Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. **2004**, 364, 1757-65 1229
- 1665 Nonabsorbable disaccharides for hepatic encephalopathy. **2004**, CD003044 64
- 1664 Data and safety monitoring during randomized controlled trials of nursing interventions. **2004**, 53, 414-8 6
- 1663 A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. **2004**, 103, 851-9 81
- 1662 Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. **2004**, 104, 1559-64 170
- 1661 Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. **2004**, 104, 1253-7 93

1660	Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. 2004 , 113, 1209-15		142
1659	A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. 2004 , 113, 559-64		143
1658	Methodology for small clinical trials. 2004 , 59, 273-9, 281-6		10
1657	Methodology for Small Clinical Trials. 2004 , 59, 281-286		4
1656	Alpha-Spending Function. 2005 , 1-10		
1655	Futility Analysis. 2005 , 1-11		
1654	Adaptive and Dynamic Methods of Treatment Assignment. 2005 ,		
1653	Sequential Analysis. 2005 ,		2
1652	Lan-DeMets Alpha-Spending Function. 2005 , 1-10		
1651	Staggered Entry. 2005 ,		
1650	Sequential Methods for Clinical Trials. 2005 ,		
1649	Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). 2005 , 66, 149-57		91
1648	Comparison of numerical algorithms for bivariate sequential tests based on marginal criteria. 2005 , 49, 631-641		
1647	Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. 2005 , 67, 2361-7		187
1646	Continuous toxicity monitoring in phase II trials in oncology. <i>Biometrics</i> , 2005 , 61, 540-5	1.8	44
1645	Simultaneous group sequential analysis of rank-based and weighted Kaplan-Meier tests for paired censored survival data. <i>Biometrics</i> , 2005 , 61, 715-20	1.8	5
1644	A note on P-values under group sequential testing and nonproportional hazards. <i>Biometrics</i> , 2005 , 61, 546-51	1.8	7
1643	Bayesian monitoring of clinical trials with failure-time endpoints. <i>Biometrics</i> , 2005 , 61, 239-45	1.8	17

1642	Role of the industry sponsor: protection of human subjects in early device-application studies. 2005 , 145, 17-20	
1641	Potassium sorbate reduces gastric colonization in patients receiving mechanical ventilation. 2005 , 20, 281-7	5
1640	Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting. 2005 , 130, 1319	64
1639	Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. 2005 , 41, 572-8	156
1638	Repeated looks at accumulating data: to correct or not to correct?. 2005 , 20, 205-11	4
1637	HEGPOL: randomized, placebo controlled, multicenter, double-blind clinical trial to investigate hepatoprotective effects of glycine in the postoperative phase of liver transplantation [ISRCTN69350312]. 2005 , 5, 18	32
1636	Data Monitoring Committees. 2005 ,	
1635	Interim Analysis of Censored Data. 2005 ,	
1634	Flexible Designs. 2005 , 1-14	
1633	CaseControl Study, Sequential. 2005 ,	
1632	Data and Safety Monitoring. 2005 ,	
1631	Group Sequential Tests. 2005 ,	
1630	Clinical Trials, History of. 2005 ,	0
1629	Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. 2005 , 23, 990-8	44
1628	Where's the utility in Bayesian data-monitoring of clinical trials?. 2005 , 2, 197-205; discussion 205-8	8
1627	In Reply:. 2005 , 23, 8272-8275	4
1626	Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 2005 , 23, 3752-9	146
1625	A general formulation for a one-sided group sequential design. 2005 , 2, 519-28	9

1624	Preliminary data release for randomized clinical trials of noninferiority: a new proposal. 2005 , 23, 5831-6	16
1623	Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. 2005 , 2, 413-22	41
1622	Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. 2005 , 23, 6881-9	527
1621	Inhaled nitric oxide for premature infants with severe respiratory failure. 2005 , 353, 13-22	252
1620	Self-designing trial combined with classical group sequential monitoring. 2005 , 15, 667-75	11
1619	Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. 2005 , 23, 1125-35	221
1618	Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. 2005 , 353, 238-48	1937
1617	Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 2005 , 352, 225-37	4876
1616	A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. 2005 , 353, 2747-57	1309
1615	Two-stage adaptive design for clinical trials with survival data. 2005 , 15, 707-18	28
1614	Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. 2005 , 23, 3562-7	359
1613	Anticoagulation in ischemic stroke: opportunities in arterial disease. 2005 , 20 Suppl 2, 101-8	3
1612	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. 2005 , 23, 2191-200	87
1611	Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection. 2005 , 161, 595-603	5
1610	Group sequential methods for cluster randomization trials with binary outcomes. 2005 , 2, 479-87	12
1609	Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. 2005 , 23, 4110-6	192
1608	On group sequential procedures under variance heterogeneity. 2005 , 14, 121-8	5
1607	Applying a phase II futility study design to therapeutic stroke trials. 2005 , 36, 2410-4	52

1606	Multiplicity in randomised trials II: subgroup and interim analyses. 2005 , 365, 1657-61	249
1605	Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. 2005 , 366, 643-8	1645
1604	A New Interim Monitoring Statistic for Group Sequential Clinical Trials. 2005 , 33, 153-164	
1603	How much do we have to pay for how many interim analyses?. 2005 , 26, 113-6	0
1602	Issues in the design of multisite clinical trials of psychotherapy: VA Cooperative Study No. 494 as an example. 2005 , 26, 626-36	36
1601	Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreal injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. 2005 , 140, 573-84	115
1600	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. 2005 , 352, 2487-98	2097
1599	Effect of information on reported adverse events in a placebo-controlled trial. 2005 , 28, 81-7	2
1598	A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. 2005 , 173, 1186-91	107
1597	Sample Size Determination for Clinical Trials. 2005 ,	1
1596	Current controversies in data monitoring for clinical trials. 2006 , 3, 513-21	61
1595	Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. 2006 , 24, 3347-53	179
1594	Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both <i>Streptococcus pneumoniae</i> and non-typable <i>Haemophilus influenzae</i> : a randomised double-blind efficacy study. 2006 , 367, 740-8	542
1593	Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. 2006 , 367, 1665-73	792
1592	Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 2006 , 368, 1155-63	697
1591	Adaptive trials. 2006 , 4, 215-6	
1590	High resolution colonoscopy with chromoscopy versus standard colonoscopy for the detection of colonic neoplasia: a randomized study. 2006 , 4, 349-54	123
1589	Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. 2006 , 4, 860-5	113

1588	Rhinosinusitis: developing guidance for clinical trials. 2006 , 118, S17-61	216
1587	Statistical evaluation of HIV vaccines in early clinical trials. 2006 , 27, 147-60	9
1586	A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). 2006 , 42, 179-85	12
1585	Study of the Therapeutic Effects of Intercessory Prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer. 2006 , 151, 934-42	164
1584	Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. 2006 , 113, 1974-86	65
1583	Rhinosinusitis: Developing guidance for clinical trials. 2006 , 135, S31-80	77
1582	Flexible Designs. 2006 ,	
1581	Adaptive Dose-Response Studies. 2006 , 40, 451-461	39
1580	Group Sequential Tests. 2006 ,	
1579	Sequential Analysis of Quality of Life Rasch Measurements. 2006 , 421-439	1
1578	Adaptive Designs: Terminology and Classification. 2006 , 40, 425-435	98
1577	A Review of: Analysis of Clinical Trials Using SAS: A Practical Guide, by A. Dmitrienko, G. Molenberghs, C. Chuang-Stein, and W. Offen 2006 , 16, 265-267	0
1576	Early labor assessment and support at home versus telephone triage: a randomized controlled trial. 2006 , 108, 1463-9	39
1575	Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. 2006 , 34, 2325-33	370
1574	Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. 2006 , 13, 744-59	44
1573	Early ductal decompression versus conservative management for gallstone pancreatitis with ampullary obstruction: a prospective randomized clinical trial. 2006 , 243, 33-40	89
1572	A randomized clinical trial of unfractionated heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308]. 2006 , 7, 19	9
1571	The reassessment of trial perspectives from interim data--a critical view. 2006 , 25, 23-36	76

1570	Bayesian predictive approach to interim monitoring in clinical trials. 2006 , 25, 2178-95		79
1569	Information-based monitoring of clinical trials. 2006 , 25, 3236-44; discussion 3320-5, 3326-47		22
1568	Issues in the use of adaptive clinical trial designs. 2006 , 25, 3270-96; discussion 3302-4, 3320-5, 3326-47		26
1567	Planning for an adaptive design: a case study in COPD. 2006 , 5, 135-44		1
1566	A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. 2006 , 46, 934-41		24
1565	Multistage evaluation of measurement error in a reliability study. <i>Biometrics</i> , 2006 , 62, 1190-6	1.8	6
1564	Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. 2006 , 97, 1105-10		25
1563	Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. 2006 , 23, 303-12		73
1562	FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). 2006 , 94, 798-805		281
1561	A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome. 2006 , 60, 1266-76		43
1560	Optimization of sample size in controlled experiments: the CLAST rule. 2006 , 38, 65-76		16
1559	Usefulness of vasopressin administered with epinephrine during out-of-hospital cardiac arrest. 2006 , 98, 1316-21		86
1558	Benefits and harms of perioperative beta-blockade. 2006 , 20, 285-302		12
1557	Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials. 2006 , 48, 521-36		8
1556	The likelihood as statistical evidence in multiple comparisons in clinical trials: no free lunch. 2006 , 48, 346-55		5
1555	A brief review on software developments for group sequential and adaptive designs. 2006 , 48, 732-7		33
1554	An overview of statistical approaches for adaptive designs and design modifications. 2006 , 48, 507-20		19
1553	A class of sequential tests for two-sample composite hypotheses. 2006 , 34, 217-232		8

1552	Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. 2006 , 20, 1281-8	66
1551	CD4+ count-guided interruption of antiretroviral treatment. 2006 , 355, 2283-96	1784
1550	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). 2006 , 17, 1546-52	30
1549	Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. 2006 , 113, 1164-70	193
1548	Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. 2006 , 1, 467-74	87
1547	Comparison of two fluid-management strategies in acute lung injury. 2006 , 354, 2564-75	3119
1546	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. 2006 , 24, 3121-7	1036
1545	Challenges in the design and conduct of a randomized study of two interventions for liquid aspiration. 2006 , 3, 457-68	19
1544	Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. 2006 , 24, 2879-84	80
1543	The WIZARD Trial as a Case Study of Flexible Clinical Trial Design. 2006 , 40, 345-353	5
1542	Pivotal Quantities Based on Sequential Data: A Bootstrap Approach. 2006 , 35, 1005-1018	
1541	Futility approaches to interim monitoring by data monitoring committees. 2006 , 3, 522-9	36
1540	18 Definitive Phase III and Phase IV Clinical Trials. 2007 , 546-568	
1539	Practical Bayesian design and analysis for drug and device clinical trials. 2008 , 18, 54-80	44
1538	A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome. 2007 , 4, 140-53	3
1537	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. 2007 , 356, 2271-81	3025
1536	A procedure for group sequential comparative poisson trials. 2007 , 17, 869-81	5
1535	Nonconventional clinical trial designs: approaches to provide more precise estimates of treatment effects with a smaller sample size, but at a cost. 2007 , 38, 804-8	13

1534	Neurocognitive outcomes are not improved by 17beta-estradiol in postmenopausal women undergoing cardiac surgery. 2007 , 38, 2048-54	20
1533	Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. 2007 , 109, 885-94	76
1532	A comparison of three initial antiretroviral AIDS regimens. 2007 , 357, 1056-7	5
1531	Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. 2007 , 357, 1000-8	356
1530	Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 2007 , 357, 2227-36	364
1529	Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. 2007 , 25, 3892-901	551
1528	p-Value calculation for multi-stage additive tests. 2007 , 77, 1057-1064	5
1527	Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. 2007 , 18, 263-8	88
1526	Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. 2007 , 17, 1201-10	50
1525	16 Sequential and Group Sequential Designs in Clinical Trials: Guidelines for Practitioners. 2007 , 27, 491-512	1
1524	Statistical analysis for two-stage seamless design with different study endpoints. 2007 , 17, 1163-76	20
1523	A Group Sequential Procedure for Continuous Longitudinal Data in Multi-Armed Trials. 2007 ,	
1522	Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. 2007 , 116, 1555-62	394
1521	A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. 2007 , 44, 213-9	69
1520	Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. 2007 , 25, 247-56	256
1519	Nonparametric Sequential Comparison of Two Treatments with Random Allocation. 2007 , 26, 71-87	1
1518	Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. 2007 , 4, 5-14	32
1517	Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. 2007 , 25, 4187-93	61

1516	Adaptive design: estimation and inference with censored data in a semiparametric model. 2007 , 8, 306-22	5
1515	Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. 2007 , 4, 207-17	19
1514	Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls. 2007 , 4, 598-610	2
1513	Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. 2007 , 25, 2212-7	467
1512	Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. 2007 , 25, 4466-71	45
1511	Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. 2007 , 13, 5816-24	80
1510	The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults: Response to Tournis and Mitrakou. 2007 , 30, e82-e82	2
1509	Data Monitoring in Clinical Trials Using Prediction. 2007 , 41, 733-742	16
1508	Dose Finding Studies. 2007 , 1	
1507	On the Efficiency of Interim Analyses Applied to Nonclinical Studies. 2007 , 41, 517-526	3
1506	Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. 2007 , 21, 325-33	20
1505	Does a biologic prosthesis really reduce recurrence after laparoscopic paraesophageal hernia repair?. 2007 , 246, 1116-7; author reply 1117-8	3
1504	An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naïve patients with metastatic breast cancer. 2007 , 18, 1213-9	6
1503	Reihe Epidemiologie 5 Multiplizität in randomisierten Studien II: Subgruppenanalysen und Zwischenauswertungen. 2007 , 101, 51-58	
1502	Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. 2007 , 114, 1653-62	71
1501	Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. 2007 , 153, 201-11	174
1500	Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION); design and rationale. 2007 , 154, 46-53	13
1499	Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. 2007 , 154, 624-31	190

1498	Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. 2007 , 143, 9-22	247
1497	Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. 2007 , 3, 573-84	59
1496	Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study. 2007 , 28, 48-58	18
1495	A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. 2007 , 28, 532-9	54
1494	Flexible design of two-stage adaptive procedures for phase III clinical trials. 2007 , 28, 500-13	1
1493	Group sequential t-test for clinical trials with small sample sizes across stages. 2007 , 28, 563-71	10
1492	[Analyzing clinical trials: subgroup, stratified, and intermediate analyses, and composite outcome criteria]. 2007 , 36, 519-23	1
1491	Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. 2007 , 369, 657-66	1689
1490	Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. 2007 , 369, 1431-1439	282
1489	Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. 2007 , 370, 251-261	276
1488	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. 2007 , 370, 240-250	453
1487	Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. 2007 , 370, 676-84	397
1486	Zoledronic acid and clinical fractures and mortality after hip fracture. 2007 , 357, 1799-809	1410
1485	Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. 2007 , 25, 1539-44	1883
1484	Adaptive group sequential test for clinical trials with changing patient population. 2007 , 17, 1227-38	15
1483	Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. 2007 , 4, 661-73	27
1482	Strategies for including patients recruited during interim analysis of clinical trials. 2007 , 17, 1211-25	8
1481	F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). 2007 , 50, 2002-12	328

1480	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. 2007 , 357, 2666-76	2529
1479	Stopping Boundaries. 2007 ,	
1478	Interim Analyses. 2007 ,	
1477	Flexible Designs. 2007 ,	
1476	Group Sequential Designs. 2007 ,	
1475	Futility Analysis. 2007 , 1	
1474	Maximum Duration and Information Trials. 2007 , 1	
1473	Maximum Duration and Information Trials. 2007 ,	
1472	Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure. 2007 , 49, 351-64	3
1471	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. 2007 , 110, 752-8	35
1470	ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. 2007 , 49, 391-402, 402.e1-2	448
1469	Bayes optimal sequential trial designs. 2007 , 137, 1129-1137	2
1468	Investigating the effect of intra-operative infiltration with local anaesthesia on the development of chronic postoperative pain after inguinal hernia repair. A randomized placebo controlled triple blinded and group sequential study design [NCT00484731]. 2007 , 7, 22	12
1467	Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction. 2007 , 8, 27	11
1466	Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis. 2007 , 26, 1450-61	3
1465	A comparison of adaptive allocation rules for group-sequential binary response clinical trials. 2007 , 26, 1937-54	11
1464	A 25-year review of sequential methodology in clinical studies. 2007 , 26, 237-52	40
1463	Sequential evaluation of a medical diagnostic test with binary outcomes. 2007 , 26, 4416-27	3

1462	Frequentist evaluation of group sequential clinical trial designs. 2007 , 26, 5047-80	62
1461	Implementing a decision-theoretic design in clinical trials: why and how?. 2007 , 26, 4939-57	2
1460	Repeated confidence intervals for adaptive group sequential trials. 2007 , 26, 5422-33	27
1459	Review: clinical trials in peptic ulcer disease--problems of methodology and interpretation. 1987 , 1, 91-123	3
1458	Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. 1989 , 3, 59-67	13
1457	Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. 2007 , 26, 1237-49	29
1456	A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. 2007 , 27, 492-503	89
1455	Heavy silicone oil versus standard silicone oil as vitreous tamponade in inferior PVR (HSO Study): design issues and implications. 2007 , 85, 623-30	32
1454	Sequential monitoring of randomization tests: stratified randomization. <i>Biometrics</i> , 2007 , 63, 865-72	1.8 6
1453	The albumin in acute stroke trial (ALIAS); design and methodology. 2007 , 2, 214-9	20
1452	The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 2007 , 134, 1540-7	136
1451	Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. 2007 , 6, 29-38	216
1450	Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. 2007 , 6, 115-24	178
1449	Extending the CLAST sequential rule to one-way ANOVA under group sampling. 2007 , 39, 86-100	7
1448	Randomized double-blind placebo-controlled trial of transdermal nitroglycerin for preterm labor. 2007 , 196, 37.e1-8	49
1447	A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. 2007 , 197, 396.e1-9	120
1446	A group sequential test for the inverse Gaussian mean. 2007 , 49, 377-386	6
1445	Completeness and unbiased estimation of mean vector in the multivariate group sequential case. 2007 , 98, 505-516	1

1444	Hand-assisted laparoscopic vs. laparoscopic colorectal surgery: a multicenter, prospective, randomized trial. 2008 , 51, 818-26; discussion 826-8	145
1443	Wilcoxon-based group sequential designs for comparison of areas under two correlated ROC curves. 2008 , 27, 213-23	9
1442	Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods. 2008 , 27, 1646-66	7
1441	Comments on Bayesians in clinical trials: Asleep at the switch by Lemuel A. Moy Statistics in Medicine. 2008 , 27, 483-487	1
1440	Efficient adaptive designs with mid-course sample size adjustment in clinical trials. 2008 , 27, 1593-611	24
1439	Nonparametric sequential evaluation of diagnostic biomarkers. 2008 , 27, 1667-78	11
1438	Bayesian adaptive model selection for optimizing group sequential clinical trials. 2008 , 27, 5586-604	24
1437	Sequential design approaches for bioequivalence studies with crossover designs. 2008 , 7, 245-62	51
1436	A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. 2008 , 112, 331-9	33
1435	Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. 2008 , 14, 1413-8	37
1434	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. 2008 , 59, 1796-804	107
1433	Group sequential and adaptive designs - a review of basic concepts and points of discussion. 2008 , 50, 541-57	32
1432	Burden of bioinformatics in medical research: Statistical perspectives and controversies. 2008 , 138, 450-463	
1431	Resuscitation Outcomes Consortium (ROC) PRIMED cardiac arrest trial methods part 2: rationale and methodology for "Analyze Later vs. Analyze Early" protocol. 2008 , 78, 186-95	36
1430	Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092). 2008 , 72, 644-9	54
1429	Interventions for twin-twin transfusion syndrome: a Cochrane review. 2008 , 31, 701-11	121
1428	Dynamic comparison of Kaplan-Meier proportions: monitoring a randomized clinical trial with a long-term binary endpoint. <i>Biometrics</i> , 2008 , 64, 189-97	1.8 1
1427	Simple, defensible sample sizes based on cost efficiency. <i>Biometrics</i> , 2008 , 64, 577-85; discussion 586-94	1.8 55

1426	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. 2008 , 98, 71-6	36
1425	Two-stage group sequential robust tests in family-based association studies: controlling type I error. 2008 , 72, 557-65	6
1424	Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. 2008 , 8, 40	74
1423	A community intervention trial of multimodal suicide prevention program in Japan: a novel multimodal community intervention program to prevent suicide and suicide attempt in Japan, NOCOMIT-J. 2008 , 8, 315	21
1422	Hypertonic resuscitation: design and implementation of a prehospital intervention trial. 2008 , 206, 220-32	55
1421	North Central Cancer Treatment Group--achievements and perspectives. 2008 , 35, 530-44	4
1420	Sorafenib in advanced hepatocellular carcinoma. 2008 , 359, 378-90	9089
1419	Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. 2008 , 359, 463-72	371
1418	Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. 2008 , 51, 1073-9	399
1417	Clinical efficacy of dexmedetomidine alone is less than propofol for conscious sedation during ERCP. 2008 , 67, 651-9	66
1416	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. 2008 , 359, 906-17	1580
1415	Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. 2008 , 61, 324-30	50
1414	Early stopping of randomized clinical trials for overt efficacy is problematic. 2008 , 61, 241-6	97
1413	Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. 2008 , 155, 215-23	137
1412	Rationale and design of the Home Automatic External Defibrillator Trial (HAT). 2008 , 155, 445-54	9
1411	Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. 2008 , 26, 300-7	2
1410	Effectiveness of leech therapy in women with symptomatic arthrosis of the first carpometacarpal joint: a randomized controlled trial. 2008 , 137, 452-459	41
1409	A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. 2008 , 358, 2319-31	883

1408	Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 2008 , 44, 808-18	381
1407	Implementing type I & type II error spending for two-sided group sequential designs. 2008 , 29, 351-8	7
1406	Bayesian interim analysis in clinical trials. 2008 , 29, 751-5	7
1405	Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. 2008 , 371, 49-56	127
1404	Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. 2008 , 371, 2109-19	363
1403	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. 2008 , 372, 449-56	2451
1402	Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. 2008 , 372, 1977-87	414
1401	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). 2008 , 9, 105-16	817
1400	Considerations in adapting clinical trial design. 2008 , 107, 14-8	
1399	[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]. 2008 , 25, 91-6	4
1398	Pharmacometrics: The Science of Quantitative Pharmacology. 2008 , 103, 431-432	
1397	A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor. 2008 , 18, 737-49	
1396	Adaptive Design Methods in Clinical Trials. 2008 , 103, 431-431	
1395	Statistical Monitoring of Clinical Trials: A Unified Approach. 2008 , 103, 430-431	
1394	A randomized trial of arthroscopic surgery for osteoarthritis of the knee. 2008 , 359, 1097-107	483
1393	Weighted Logrank Statistics in Sequential Tests. 2008 , 27, 97-104	3
1392	A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial. 2008 , 18, 1136-49	9
1391	Discussion on Second-Guessing Clinical Trial Designs by Jonathan J. Shuster and Myron N. Chang. 2008 , 27, 30-32	

1390	Multi-arm clinical trials of new agents: some design considerations. 2008 , 14, 4368-71	104
1389	Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. 2008 , 26, 1086-92	1027
1388	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 2008 , 26, 1642-9	481
1387	Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. 2008 , 26, 2320-6	40
1386	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. 2008 , 26, 4092-9	82
1385	Sequential Monitoring of Conditional Randomization Tests: Generalized Biased Coin Designs. 2008 , 27, 234-253	1
1384	Editor's Special Invited Paper: Second-Guessing Clinical Trial Designs. 2008 , 27, 2-20	2
1383	Sample size re-estimation for adaptive sequential design in clinical trials. 2008 , 18, 1184-96	77
1382	Efficient Error Determination in Sequential Clinical Trial Design. 2008 , 17, 925-948	1
1381	Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. 2008 , 122 Suppl 5, S240-50	82
1380	Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 2008 , 26, 5043-51	696
1379	Interim futility analysis with intermediate endpoints. 2008 , 5, 14-22	35
1378	Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. 2008 , 1, 32-8	399
1377	Maintaining confidentiality of interim data to enhance trial integrity and credibility. 2008 , 5, 157-67	43
1376	Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. 2008 , 100, 996-1002	239
1375	Home use of automated external defibrillators for sudden cardiac arrest. 2008 , 358, 1793-804	203
1374	Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. 2008 , 112, 1303-1310	74
1373	Lan-DeMets Alpha-Spending Function. 2008 , 1	

1372 Alpha-Spending Function. **2008**, 1

1371 Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. **2008**, 111, 2556-62 235

1370 A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. **2008**, 19, 739-44 23

1369 Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. **2008**, 111, 77-87 200

1368 Drift (For Interim Analysis). **2008**, 1

1367 Sequential Analysis. **2008**, 1

1366 SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. **2008**, 3, e1474 212

1365 Data Monitoring Committee. **2008**, 1

1364 Vaccine prevention of maternal cytomegalovirus infection. **2009**, 360, 1191-9 523

1363 A randomized trial of vertebroplasty for osteoporotic spinal fractures. **2009**, 361, 569-79 1034

1362 Sequential Tests and Change Detection in the Covariance Structure of Weakly Stationary Time Series. **2009**, 38, 2872-2883 5

1361 A simulation study on power comparisons for group sequential tests of non-parametric statistics. **2009**, 79, 769-785 1

1360 Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. **2009**, 101, 142-52 215

1359 A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. **2009**, 20, 1560-1564 16

1358 A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. **2009**, 100, 291-7 75

1357 Approximately Optimal Continuous Stopping Boundaries in a One-Sided Standard Sequential Test. **2009**, 28, 426-433

1356 Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. **2009**, 38, 287-98 624

1355 Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). **2009**, 120, 1036-40 101

1354	Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. 2009 , 27, 1543-4	5
1353	Randomized trial of the effect of contact lens wear on self-perception in children. 2009 , 86, 222-32	57
1352	Coronary bypass surgery with or without surgical ventricular reconstruction. 2009 , 360, 1705-17	518
1351	Defibrillator implantation early after myocardial infarction. 2009 , 361, 1427-36	455
1350	Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials. 2009 , 1, 348-355	11
1349	Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. 2009 , 32, 163-7	120
1348	Recombinant human erythropoietin in the treatment of acute ischemic stroke. 2009 , 40, e647-56	448
1347	Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials.gov no. NCT00133160). 2009 , 32, 575-80	17
1346	Stopping a trial early in oncology: for patients or for industry?. 2009 , 20, 395-6	2
1345	The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. 2009 , 94, 538-44	89
1344	Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. 2009 , 34, 999-1010	62
1343	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. 2009 , 20, 935-40	157
1342	Early stopping rules in clinical trials based on sequential monitoring of serious adverse events. 2009 , 29, 343-50	8
1341	Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. 2009 , 27, 1712-21	32
1340	Stopping clinical trials early for benefit: impact on estimation. 2009 , 6, 119-25	47
1339	Prospective randomized controlled multi-centre trial of cuffed or uncuffed endotracheal tubes in small children. 2009 , 103, 867-73	226
1338	Commentary: Which meta-analyses are conclusive?. 2009 , 38, 298-303	21
1337	Stopping trials for efficacy: an almost unbiased view. 2009 , 6, 133-5	13

1336	Optimizing trial design: sequential, adaptive, and enrichment strategies. 2009 , 119, 597-605	100
1335	Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. 2009 , 38, 276-86	594
1334	Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 2009 , 27, 5431-8	268
1333	Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial. 2009 , 113, 276-83	23
1332	Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. 2009 , 154, 514-520.e4	276
1331	Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. 2009 , 9, 50	60
1330	Impact of 4.0% chlorhexidine cleansing of the umbilical cord on mortality and omphalitis among newborns of Sylhet, Bangladesh: design of a community-based cluster randomized trial. 2009 , 9, 67	25
1329	Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. 2009 , 208, 1-13	270
1328	Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. 2009 , 208, 725-35; discussion 735-7	99
1327	Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. 2009 , 55, 1135-43	46
1326	Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. 2009 , 55, 1112-23	125
1325	Scope and design of the Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements (FREEDOM) Study. 2009 , 53, 310-20	40
1324	A possible association between aprotinin and improved survival after radical surgery for mesothelioma. 2009 , 115, 833-41	14
1323	Target hemoglobin trials in chronic kidney disease: design and interpretation issues. 2009 , 24, 2279-85	2
1322	Dosisverhoging SSRI's bij depressie is niet zinvol. 2009 , 52, 289-296	
1321	Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale. 2009 , 23, 243-7	12
1320	Further Comments on the Alpha-Spending Function. 2009 , 1, 95-111	5
1319	Ethics and Stopping Rules in a Phase II Clinical Trial. 2009 , 22, 39-44	0

1318	Dose selection in seamless phase II/III clinical trials based on efficacy and safety. 2009 , 28, 917-36	25
1317	Adaptive designs for confirmatory clinical trials. 2009 , 28, 1181-217	192
1316	Using short-term response information to facilitate adaptive randomization for survival clinical trials. 2009 , 28, 1680-9	41
1315	Fitting spending functions. 2010 , 29, 321-7	5
1314	Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. 2009 , 8, 136-49	10
1313	The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials. 2010 , 9, 151-61	
1312	Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) - study design. 2009 , 32, 987-94	66
1311	A randomized trial comparing sevoflurane and propofol in children undergoing MRI scans. 2009 , 19, 672-81	54
1310	Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. 2009 , 7, 58-64	169
1309	Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy. 2009 , 14, 191-9	6
1308	Randomized double masked trial of Zhi Byed 11, a Tibetan traditional medicine, versus misoprostol to prevent postpartum hemorrhage in Lhasa, Tibet. 2009 , 54, 133-141.e1	19
1307	A random walk approach for quantifying uncertainty in group sequential survival trials. 2009 , 53, 609-620	3
1306	Group sequential testing of homogeneity in genetic linkage analysis. 2009 , 53, 3630-3639	4
1305	Change in criteria for USP dissolution performance verification tests. 2009 , 10, 21-6	1
1304	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. 2009 , 45, 1589-96	59
1303	Adaptive trial design: a general methodology for censored time to event data. 2009 , 30, 171-7	19
1302	Adverse effects of combined spinal-epidural versus traditional epidural analgesia during labor. 2009 , 106, 242-5	18
1301	[Sequential designs and intermediate analysis in clinical research: size vs difficulty]. 2009 , 132, 437-42	3

1300	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. 2009 , 157, 606-12	101
1299	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. 2009 , 158, 327-334.e4	111
1298	Clinical trials in rehabilitation: single or multiple outcomes?. 2009 , 90, S17-21	25
1297	Extended-release niacin or ezetimibe and carotid intima-media thickness. 2009 , 361, 2113-22	534
1296	Sequential Design for Microarray Experiments. 2009 , 104, 650-660	20
1295	Ethics and Stopping Rules in a Phase II Clinical Trial. 2009 , 22, 39-44	
1294	Analysis of Longitudinal Ordinal Data with Drop-Outs. 2009 ,	
1293	The MRC superficial bladder cancer trial of intravesical mytomicin-c after complete surgical resection. Sequential statistical methods applied to survival data from a randomised clinical trial. 2009 , 7, 441-5	2
1292	Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. 2009 , 10, 100-8	99
1291	Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. 2009 , 373, 1364-71	52
1290	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. 2009 , 374, 222-8	376
1289	Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. 2009 , 374, 119-25	167
1288	Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group trial. 2009 , 374, 1074-81	140
1287	Screening and prostate-cancer mortality in a randomized European study. 2009 , 360, 1320-8	2828
1286	The USA Multicenter Prehospital Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results. 2009 , 25, 325-56, Table of Contents	25
1285	Is "rescue" therapy ethical in randomized controlled trials?. 2009 , 10, 431-8	18
1284	Unfractionated heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). 2009 , 37, 1185-96	117
1283	Nonproportional Hazards and the Power of Sequential Trials. 2009 , 1, 66-73	2

1282	Bridging clinical investigators and statisticians: writing the statistical methodology for a research proposal. 2009 , 57, 818-24	22
1281	References. 2009 , 269-275	
1280	A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer. 2010 , 5, 993-1000	7
1279	Critical care trial design and interpretation: a primer. 2010 , 38, 1882-9	6
1278	Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. 2010 , 5, 110-6	29
1277	The false discovery rate: a key concept in large-scale genetic studies. 2010 , 17, 58-62	37
1276	Group Sequential Methods in Biomedical Research. 2010 , 1	
1275	Comparison of Twin-block and Dynamax appliances for the treatment of Class II malocclusion in adolescents: a randomized controlled trial. 2010 , 138, 144.e1-9; discussion 144-5	15
1274	Challenges and recommendations for blinding in behavioral interventions illustrated using a case study of a behavioral intervention to lower blood pressure. 2010 , 78, 5-11	28
1273	Group sequential tests under fractional Brownian motion in monitoring clinical trials. 2010 , 19, 277-286	5
1272	Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial. 2010 , 160, 526-34	6
1271	Sequential Testing with Recurrent Events over Multiple Treatment Periods. 2010 , 2, 137-153	4
1270	Approximating probabilities of correlated events. 2010 , 53, 2937-2948	1
1269	Adaptive group sequential confidence intervals for the ratio of normal means. 2010 , 72, 76-95	
1268	Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. 2010 , 9, 959-68	362
1267	Cancer screening trials: nuts and bolts. 2010 , 37, 216-23	12
1266	Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. 2010 , 10, 478	66
1265	Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. 2010 , 10, 606	47

1264	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. 2010 , 116, 3969-77	94
1263	Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. 2010 , 16, 1947-56	40
1262	A group sequential type design for three-arm non-inferiority trials with binary endpoints. 2010 , 52, 504-18	10
1261	Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials. 2010 , 52, 798-810	17
1260	Adaptive confidence intervals of desired length and power for normal means. 2010 , 140, 3317-3325	2
1259	Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. 2010 , 11, 113	3
1258	The dual test: safeguarding p-value combination tests for adaptive designs. 2010 , 29, 797-807	3
1257	Hierarchical testing of multiple endpoints in group-sequential trials. 2010 , 29, 219-28	57
1256	A conditional maximized sequential probability ratio test for pharmacovigilance. 2010 , 29, 284-95	62
1255	Optimal group-sequential designs for simultaneous testing of superiority and non-inferiority. 2010 , 29, 743-59	14
1254	Some drop-the-loser designs for monitoring multiple doses. 2010 , 29, 1793-807	11
1253	Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. 2010 , 29, 1761-8	21
1252	Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). 2010 , 5, 40-6	77
1251	Testing a primary and a secondary endpoint in a group sequential design. <i>Biometrics</i> , 2010 , 66, 1174-84 1.8	47
1250	Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). 2010 , 122, 345-55	48
1249	Surgical management of subfoveal choroidal neovascular membranes in age-related macular degeneration by macular relocation: experiences of an early-stopped randomised clinical trial (MARAN Study). 2010 , 24, 284-9	2
1248	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. 2010 , 106, 966-73	81
1247	Group Sequential Tests. 2010 , 1	

1246	Sequential monitoring of response-adaptive randomized clinical trials. 2010 , 38,	28
1245	Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. 2010 , 28, 1645-51	237
1244	A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. 2010 , 21, 540-547	46
1243	Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. 2010 , 5, 1928-38	31
1242	Randomized clinical trials with biomarkers: design issues. 2010 , 102, 152-60	267
1241	Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. 2010 , 182, 1058-64	250
1240	Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. 2010 , 362, 427-39	411
1239	Skin-to-skin contact after cesarean delivery: an experimental study. 2010 , 59, 78-84	52
1238	Insights from the conduct of a device trial in older persons: low magnitude mechanical stimulation for musculoskeletal health. 2010 , 7, 354-67	17
1237	B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. 2010 , 121, 1432-8	95
1236	Nonadministration of routine probiotics unethical--really?. 2010 , 126, e740-1; author reply e743-5	16
1235	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. 2010 , 28, 1547-53	422
1234	The randomized shortened dental arch study: tooth loss. 2010 , 89, 818-22	31
1233	Operating Characteristics for Group Sequential Trials Monitored Under Fractional Brownian Motion. 2010 , 39, 705-712	7
1232	Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. 2010 , 362, 2271-81	356
1231	Review of draft FDA adaptive design guidance. 2010 , 20, 1132-42	25
1230	Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. 2010 , 182, 1123-8	141
1229	Overlapping compared with end-to-end repair of third- and fourth-degree obstetric anal sphincter tears: a randomized controlled trial. 2010 , 116, 16-24	23

1228	A general inefficacy interim monitoring rule for randomized clinical trials. 2010 , 7, 197-208	45
1227	Adaptive Choice of Group Sequential Boundary. 2010 , 2, 199-219	
1226	A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-sample Analysis. 2010 , 2, 336-347	
1225	Stenting versus endarterectomy for treatment of carotid-artery stenosis. 2010 , 363, 11-23	2055
1224	Monitoring Response Variables. 2010 , 293-343	1
1223	Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. 2010 , 68, 156-62	134
1222	A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. 2010 , 70, 340-6	15
1221	Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. 2010 , 139, 1198-206	278
1220	Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. 2010 , 363, 1313-23	190
1219	Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. 2010 , 94, 2596-9	83
1218	Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. 2010 , 31, 572-8	55
1217	An update on the IMPROVED reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. 2010 , 159, 705-9	77
1216	Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial. 2010 , 123, 1059.e1-8	20
1215	The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. 2010 , 55, 2721-6	174
1214	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. 2010 , 11, 543-52	432
1213	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. 2010 , 363, 411-22	3838
1212	Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 2010 , 363, 1419-28	407
1211	Development of Adaptive Group Sequential Procedure for Changing Sample Size. 2010 , 39, 950-970	

1210	Combining an Internal Pilot with an Interim Analysis for Single Degree of Freedom Tests. 2010 , 39, 3717-3738	7
1209	Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. 2011 , 21, 846-59	10
1208	Group-sequential methods for adaptive seamless phase II/III clinical trials. 2011 , 21, 787-801	12
1207	Prevention of HIV-1 infection with early antiretroviral therapy. 2011 , 365, 493-505	5157
1206	Coronary-artery bypass surgery in patients with left ventricular dysfunction. 2011 , 364, 1607-16	759
1205	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. 2011 , 8, 165-74	17
1204	Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. 2011 , 365, 787-97	185
1203	An evaluation of a Simon 2-Stage phase II clinical trial design incorporating toxicity monitoring. 2011 , 32, 428-36	5
1202	Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). 2011 , 32, 453-60	17
1201	An evaluation of a distributed medical device safety surveillance system: the DELTA network study. 2011 , 32, 309-17	18
1200	A comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials?. 2011 , 32, 561-8	8
1199	Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations. 2011 , 32 Suppl 1, S8-10	2
1198	Vasopressors and the search for the optimal trial design. 2011 , 32, 924-30	3
1197	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. 2011 , 47, 983-9	18
1196	Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. 2011 , 20, 357-68	92
1195	Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. 2011 , 118, 1916-26	222
1194	Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. 2011 , 12, 1204-13	72
1193	Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial. 2011 , 377, 301-11	170

1192	Sequential and Group Sequential Designs in Clinical Trials Guidelines for Practitioners. 2011 , 269-290	
1191	Conduct of Stroke-Related Clinical Trials. 2011 , 1192-1203	0
1190	Bibliography. 2011 , 401-412	
1189	Pearson-Fisher Chi-Square Statistic Revisited. 2011 , 2, 528-545	47
1188	Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. 2011 , 39, 2048-58	275
1187	Repeated Confidence Intervals Under Fractional Brownian Motion in Long-Term Clinical Trials. 2011 , 40, 1130-1145	5
1186	Comparison of oral polyethylene glycol plus a large volume glycerine enema with a large volume glycerine enema alone in patients undergoing colorectal surgery for malignancy: a randomized clinical trial. 2011 , 13, e327-34	15
1185	Group sequential and adaptive designs: a novel, promising tool for nursing research. 2011 , 67, 1824-33	2
1184	SAE: an R package for early stopping rules in clinical trials. 2011 , 104, 243-8	1
1183	Sequential meta-analysis of single-case experimental data. 2011 , 43, 720-9	6
1182	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. 2011 , 68, 805-13	40
1181	A prospective, randomized, double-blind, multicenter study comparing remifentanyl with fentanyl in mechanically ventilated patients. 2011 , 37, 469-76	37
1180	A Note on Correction of Information Time in a Survival Trial Using an Alpha Spending Function. 2011 , 3, 250-259	1
1179	Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]. 2011 , 11, 19	17
1178	A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. 2011 , 11, 367	8
1177	Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial. 2011 , 12, 156	6
1176	The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial. 2011 , 12, 223	11
1175	Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. 2011 , 12, 81	45

1174	Benefits, challenges and obstacles of adaptive clinical trial designs. 2011 , 6, 79	36
1173	Sequential interim analyses of survival data in DNA microarray experiments. 2011 , 12, 127	3
1172	Sequential methods for random-effects meta-analysis. 2011 , 30, 903-21	185
1171	Adaptive increase in sample size when interim results are promising: a practical guide with examples. 2011 , 30, 3267-84	184
1170	Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings. 2011 , 30, 1199-217	11
1169	Stochastic curtailment of health questionnaires: a method to reduce respondent burden. 2011 , 30, 1989-2004	17
1168	Comments on 'Adaptive increase in sample size when interim results are promising: a practical guide with examples'. 2011 , 30, 3285-301; discussion 3302-3	26
1167	Sequential diagnostic trial designs. 2011 , 3, 79-83	4
1166	A method for calculation of optimum data size and bin size of histogram features in fault diagnosis of mono-block centrifugal pump. 2011 , 38, 7708-7717	4
1165	A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. 2011 , 78, 162-71	35
1164	Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. 2011 , 365, 1482-91	429
1163	A randomized controlled trial of genotype-based Coumadin initiation. 2011 , 13, 509-18	102
1162	On sample size determination in multi-armed confirmatory adaptive designs. 2011 , 21, 802-17	14
1161	Group Sequential Methods and Software Applications. 2011 , 65, 127-135	15
1160	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. 2011 , 16, 1092-100	181
1159	Breast-cancer adjuvant therapy with zoledronic acid. 2011 , 365, 1396-405	378
1158	Group sequential trials revisited: simple implementation using SAS. 2011 , 20, 635-56	15
1157	Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. 2011 , 53, 716-24	55

1156	Alternatives to the standard Fleming, Harrington, and O'Brien futility boundary. 2011 , 8, 270-6	17
1155	A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). 2011 , 22, 1054-1061	95
1154	Efficiency perspectives on adaptive designs in stroke clinical trials. 2011 , 42, 2990-4	18
1153	Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- γ in newly diagnosed chronic myeloid leukemia. 2011 , 29, 1634-42	271
1152	Thermal defense of extremely low gestational age newborns during resuscitation: exothermic mattresses vs polyethylene wrap. 2011 , 31, 33-7	34
1151	Statistical Inference in Adaptive Group Sequential Trials with the Standardized Mean Difference as Effect Size. 2011 , 30, 94-113	2
1150	Sequential Analysis of Censored Data with Linear Transformation Models. 2012 , 31, 172-189	
1149	Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?. 2012 , 9, e1001234	11
1148	Tight glycemic control versus standard care after pediatric cardiac surgery. 2012 , 367, 1208-19	192
1147	More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. 2012 , 6, e1545	7
1146	Traumatic brain injury in Latin America: lifespan analysis randomized control trial protocol*. 2012 , 71, 1055-63	9
1145	Influence of parenteral nutrition delivery system on the development of bloodstream infections in critically ill patients: an international, multicenter, prospective, open-label, controlled study--EPICOS study. 2012 , 36, 574-86	44
1144	Standard 4: determining adequate sample sizes. 2012 , 129 Suppl 3, S138-45	28
1143	Overestimation of the effect size in group sequential trials. 2012 , 18, 4872-6	22
1142	Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. 2012 , 6, 1305-18	18
1141	Stopping guidelines for harm in a study designed to establish the safety of a marketed drug. 2012 , 22, 338-50	2
1140	Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. 2012 , 30, 616-22	61
1139	A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. 2012 , 99, 494-501	87

1138	Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. 2012 , 30, 3841-7	96
1137	Integrated phase II/III clinical trials in oncology: a case study. 2012 , 9, 741-7	6
1136	Intermittent androgen suppression for rising PSA level after radiotherapy. 2012 , 367, 895-903	335
1135	Optimization of adaptive designs: efficiency evaluation. 2012 , 22, 641-61	1
1134	Stopping a trial early - and then what?. 2012 , 9, 714-20	10
1133	Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials. 2012 , 2012, 1-20	9
1132	An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. 2012 , 9, 377-84	2
1131	Chemotherapy for brain metastases from small cell lung cancer. 2012 , CD007464	18
1130	Effects of continuous positive airway pressure on neurocognitive function in obstructive sleep apnea patients: The Apnea Positive Pressure Long-term Efficacy Study (APPLES). 2012 , 35, 1593-602	255
1129	Sequential monitoring with conditional randomization tests. 2012 , 40,	14
1128	Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. 2012 , 31, 736-44	99
1127	Overlapping compared with end-to-end repair of complete third-degree or fourth-degree obstetric tears: three-year follow-up of a randomized controlled trial. 2012 , 120, 803-8	30
1126	References and Data Sources. 2012 , 657-663	
1125	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. 2012 , 119, 3269-75	90
1124	Statistical design and analysis issues for the ARDS Clinical Trials Network: the Coordinating Center perspective. 2012 , 2, 275-289	2
1123	Early Stopping of Clinical Trials. 2012 , 211-228	
1122	Adaptive Trial Designs. 2012 , 265-292	
1121	Software for Design and Analysis of Clinical Trials. 2012 , 305-324	

1120	Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). 2012 , 13, 1250-9	170
1119	Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. 2012 , 33, 1280-6	22
1118	The effectiveness of telehealth care on caregiver burden, mastery of stress, and family function among family caregivers of heart failure patients: a quasi-experimental study. 2012 , 49, 1230-42	57
1117	Designing group sequential randomized clinical trials with time to event end points using a R function. 2012 , 108, 113-28	3
1116	Sequential meta-analysis to determine the sufficiency of cumulative knowledge: The case of early intensive behavioral intervention for children with autism spectrum disorders. 2012 , 6, 168-176	23
1115	Design of the Trial to Assess Chelation Therapy (TACT). 2012 , 163, 7-12	54
1114	Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. 2012 , 163, 938-45	102
1113	Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach. 2012 , 33, 138-42	3
1112	Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. 2012 , 30, 3516-24	171
1111	A new futility test approach in clinical interim data monitoring. 2012 , 11, 468-75	
1110	Current issues in clinical trials: standing on the shoulders of Jerome Cornfield. 2012 , 31, 2798-804	1
1109	Impact on postpartum hemorrhage of prophylactic administration of oxytocin 10 IU via Uniject by peripheral health care providers at home births: design of a community-based cluster-randomized trial. 2012 , 12, 42	19
1108	Efficacy of early neonatal vitamin A supplementation in reducing mortality during infancy in Ghana, India and Tanzania: study protocol for a randomized controlled trial. 2012 , 13, 22	33
1107	Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial. 2012 , 13, 57	10
1106	Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. 2012 , 367, 399-410	2168
1105	Bayesian adaptive trial design for a newly validated surrogate endpoint. <i>Biometrics</i> , 2012 , 68, 258-67	1.8 7
1104	Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm—combined prospective analysis by the German AML Intergroup. 2012 , 30, 3604-10	107
1103	Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. 2012 , 11, 942-50	285

1102	Monitoring Randomized Clinical Trials. 2012 , 213-249	1
1101	Interim analysis of clinical trials based on urn models. 2012 , 40, 550-568	7
1100	Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. 2012 , 107, 389-96	40
1099	Oral cleft prevention program (OCPP). 2012 , 12, 184	24
1098	Intermediate Topics in Biostatistics. 2012 , 295-320	
1097	Monitoring of Clinical Trials:. 147-159	
1096	References. 2012 , 261-266	
1095	Selection and Futility Designs. 78-90	2
1094	Optimal multistage designs for randomised clinical trials with continuous outcomes. 2012 , 31, 301-12	29
1093	Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot. 2012 , 21 Suppl 1, 72-81	38
1092	Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. 2012 , 21 Suppl 1, 62-71	45
1091	A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. 2012 , 21 Suppl 1, 282-90	30
1090	Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials. 2012 , 11, 310-7	1
1089	Testing superiority at interim analyses in a non-inferiority trial. 2012 , 31, 1531-42	2
1088	Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. 2012 , 31, 2027-40	20
1087	Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation. 2012 , 31, 2041-54	13
1086	Spending functions and continuous-monitoring boundaries. 2012 , 31, 3024-30	1
1085	Optimal design of multi-arm multi-stage trials. 2012 , 31, 4269-79	66

1084	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. 2012 , 119, 5963-71	57
1083	Linezolid in methicillin-resistant <i>Staphylococcus aureus</i> nosocomial pneumonia: a randomized, controlled study. 2012 , 54, 621-9	414
1082	Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. 2012 , 11, 397-404	330
1081	Randomized comparison of synchronous CABG and carotid endarterectomy vs. isolated CABG in patients with asymptomatic carotid stenosis: the CABACS trial. 2012 , 7, 354-60	19
1080	Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. 2012 , 160, 929-35.e1	80
1079	A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. 2012 , 142, 944-955	1
1078	Step-up and step-down methods for testing multiple hypotheses in sequential experiments. 2012 , 142, 2059-2070	17
1077	Phase II trial design with Bayesian adaptive randomization and predictive probability. 2012 , 61, 219-35	44
1076	Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. 2013 , 382, 1341-9	196
1075	Mediolateral oversizing influences pain, function, and flexion after TKA. 2013 , 21, 2314-24	96
1074	Group sequential comparison of two binomial proportions under ranked set sampling design. 2013 , 28, 1169-1194	1
1073	A Statistical Perspective on Prevention Trials: A View from the Women's Health Initiative. 2013 , 5, 330-343	1
1072	Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials. 2013 , 13, 21	1
1071	Robust Bayesian monitoring of sequential trials. 2013 , 71, 81-95	
1070	Sequential Methods for Vaccine Safety Evaluation and Surveillance in Public Health. 2013 , 101-122	1
1069	Confidence Intervals and p-Values. 2013 , 153-186	
1068	Group sequential methods based on ranked set samples. 2013 , 54, 547-562	3
1067	Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. 2013 , 381, 2083-90	963

1066	Chronic use of Amiodarone aGAINSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial. 2013 , 166, 976-982.e4	23
1065	Multiple comparisons in complex clinical trial designs. 2013 , 55, 420-9	5
1064	Patient outcome following 2 different stress imaging approaches: a prospective randomized comparison. 2013 , 61, 2446-2455	41
1063	Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. 2013 , 14, 655-62	209
1062	A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics. 2013 , 27, 598-609	76
1061	High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. 2013 , 12, 1049-58	127
1060	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. 2013 , 31, 2404-12	119
1059	Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. 2013 , 12, 366-74	9
1058	Alpha emitter radium-223 and survival in metastatic prostate cancer. 2013 , 369, 213-23	2106
1057	Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). 2013 , 1, 308-314	51
1056	Statistical issues and challenges in immuno-oncology. 2013 , 1, 18	99
1055	Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. 2013 , 14, 400	18
1054	Robust inference from multiple test statistics via permutations: a better alternative to the single test statistic approach for randomized trials. 2013 , 12, 282-90	7
1053	A Bayesian decision-theoretic sequential response-adaptive randomization design. 2013 , 32, 1975-94	12
1052	A group sequential Holm procedure with multiple primary endpoints. 2013 , 32, 1112-24	37
1051	Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. 2013 , 31, 4067-75	564
1050	An efficient sequential design of clinical trials. 2013 , 143, 283-295	3
1049	Comparison of Operating Characteristics of Commonly Used Sample Size Re-Estimation Procedures in a Two-Stage Design. 2013 , 42, 1140-1152	2

1048	The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. 2013 , 53, 777-82	22
1047	Stress CMR reduces revascularization, hospital readmission, and recurrent cardiac testing in intermediate-risk patients with acute chest pain. 2013 , 6, 785-94	40
1046	Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. 2013 , 31, 2578-83	36
1045	Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE): a randomized controlled trial protocol. 2013 , 13, 5	38
1044	Group sequential tests for delayed responses (with discussion). 2013 , 75, 3-54	54
1043	Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. 2013 , 31, 1405-14	162
1042	Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. 2013 , 368, 893-903	1376
1041	Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. 2013 , 56, 934-42	141
1040	Primary prevention of cardiovascular disease with a Mediterranean diet. 2013 , 368, 1279-90	3041
1039	Medical Statistics. 2013 , 189-218	0
1038	Adaptive Design of Confirmatory Trials. 2013 , 187-223	
1037	Design of oncology clinical trials: a review. 2013 , 88, 144-53	18
1036	An insight into the properties of a two-stage design in bioequivalence studies. 2013 , 30, 1824-35	15
1035	International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. 2013 , 15, 974-90	65
1034	Filgrastim improves survival in lethally irradiated nonhuman primates. 2013 , 179, 89-100	108
1033	The study protocol for the LINC (LUCAS in cardiac arrest) study: a study comparing conventional adult out-of-hospital cardiopulmonary resuscitation with a concept with mechanical chest compressions and simultaneous defibrillation. 2013 , 21, 5	21
1032	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. 2013 , 10, S5-S36	87
1031	Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMiSe. 2013 , 39, 1760-75	33

1030	Advancing clinical trial design in pulmonary hypertension. 2013 , 3, 217-25	12
1029	Design of the Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST). 2013 , 38, 1832-41	40
1028	Rationale, timeline, study design, and protocol overview of the therapeutic hypothermia after pediatric cardiac arrest trials. 2013 , 14, e304-15	34
1027	The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study. 2013 , 14, 374-83	7
1026	Effects of bracing in adolescents with idiopathic scoliosis. 2013 , 369, 1512-21	577
1025	Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. 2013 , 177, 131-41	34
1024	Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. 2013 , 31, 1341-7	110
1023	Statistical challenges in the evaluation of treatments for small patient populations. 2013 , 5, 178sr3	34
1022	Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. 2013 , 57, 1542-9	108
1021	Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. 2013 , 32, 1150-63	14
1020	Early termination of a two-stage study to develop and validate a panel of biomarkers. 2013 , 32, 1027-37	9
1019	A Pocock approach to sequential meta-analysis of clinical trials. 2013 , 4, 269-79	1
1018	A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers' diarrhea. 2013 , 20, 88-94	25
1017	A note on variance estimation in the Cox proportional hazards model. 2013 , 40, 1132-1139	4
1016	Asymmetric Group Sequential Designs under Fractional Brownian Motion. 2013 , 42, 2172-2184	5
1015	Reducing the average number of patients needed in a phase II trial through novel design. 2013 , 30, 47-54	3
1014	Multiple Testing in Group Sequential Trials Using Graphical Approaches. 2013 , 5, 311-320	63
1013	Sequential Testing Theory and Stochastic Optimization Over Time. 2013 , 37-75	

1012	Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. 2013 , 60, 1108-12	79
1011	Sample size determination for group sequential test under fractional Brownian motion. 2013 , 7,	2
1010	Alpha-Spending Function. 2013 , 1	
1009	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. 2013 , 121, 5006-14	247
1008	References. 2013 , 799-844	
1007	Design and rationale of safe pediatric euglycemia after cardiac surgery: a randomized controlled trial of tight glycemic control after pediatric cardiac surgery. 2013 , 14, 148-56	8
1006	Futility Analysis. 2013 , 1	
1005	Lung cancer screening with computer aided detection chest radiography: design and results of a randomized, controlled trial. 2013 , 8, e59650	17
1004	Effectiveness of a multimodal community intervention program to prevent suicide and suicide attempts: a quasi-experimental study. 2013 , 8, e74902	37
1003	Flexible Designs. 2013 , 1	
1002	Group Sequential Designs. 2013 , 1	
1001	Flexible Designs. 2014 , 383-398	
1000	Group Sequential Designs. 2014 , 467-482	
999	Maximum Duration and Information Trials. 2014 , 515-521	
998	Sample Size Determination in Clinical Trails Including Adjustments for Noncompliance, Loss to Follow-Up and Groups Sequential Analysis. 2014 ,	
997	Fuzzy Approach for Group Sequential Test. 2014 , 2014, 1-9	0
996	Interim Analyses. 2014 , 323-333	
995	References. 2014 , 331-338	

994 Futility Analysis. **2014,**

993 Staggered Entry. **2014,**

992 Sequential Methods for Clinical Trials. **2014,**

991 Clinical Trials - Further Developments. **2014,**

990 Data Monitoring Committees. **2014,**

989 Clinical Trials, History of. **2014,**

988 Sequential Analysis - Further Developments. **2014,**

987 Group Sequential Designs. **2014,**

1

986 Sequential Analysis - Recent Advances. **2014,**

985 Data Monitoring Committees including Operational Issues. **2014,**

984 Interim Analyses. **2014,**

983 Group Sequential Methods in Biomedical Research. **2014,**

982 Randomized Controlled Trials. **2014,**

981 Comparative Efficacy Trials (Phase III Studies). **2014,**

980 Adaptive and Dynamic Methods of Treatment Assignment. **2014,**

979 CaseControl Study, Sequential. **2014,**

978 Flexible Designs. **2014,**

977 Drift (For Interim Analysis). **2014,**

976	Stopping Boundaries. 2014,	
975	Violations of the independent increment assumption when using generalized estimating equation in longitudinal group sequential trials. 2014, 33, 5041-56	2
974	Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. 2014, 24, 817-33	8
973	Guided (VENTRI-GUIDE) versus freehand ventriculostomy: study protocol for a randomized controlled trial. 2014, 15, 478	22
972	Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic. 2014, 6, 16-29	5
971	A Practical Guide to Data Monitoring Committees in Adaptive Trials. 2014, 48, 316-326	8
970	Flexibly Monitoring Group Sequential Survival Trials When Testing is Based Upon a Weighted Log-Rank Statistic. 2014, 33, 39-59	2
969	Very early administration of progesterone for acute traumatic brain injury. 2014, 371, 2457-66	374
968	Trial sequential methods for meta-analysis. 2014, 5, 212-20	43
967	An Introduction to Practical Sequential Inferences via Single-Arm Binary Response Studies Using the binseqtest R Package. 2014, 68, 230-242	3
966	A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors. 2014, 14, 621-8	33
965	An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size. <i>Biometrics</i> , 2014, 70, 556-67	1.8 6
964	Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. 2014, 168, 823-9.e6	34
963	CP function: an alpha spending function based on conditional power. 2014, 33, 4501-14	
962	Adaptive Clinical Trials: Overview of Phase III Designs and Challenges. 2014, 48, 31-40	10
961	A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events. 2014, 48, 444-452	1
960	Hierarchical nested trial design (HNTD) for demonstrating treatment efficacy of new antibacterial drugs in patient populations with emerging bacterial resistance. 2014, 33, 4321-36	7
959	Sample size determination in group-sequential clinical trials with two co-primary endpoints. 2014, 33, 2897-913	19

958	Evaluation of the impact of implementing the emergency medical services traumatic brain injury guidelines in Arizona: the Excellence in Prehospital Injury Care (EPIC) study methodology. 2014 , 21, 818-30	22
957	Likelihood ratio based tests for longitudinal drug safety data. 2014 , 33, 2408-24	15
956	Continuous sequential boundaries for vaccine safety surveillance. 2014 , 33, 3387-97	6
955	The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. 2014 , 9, 246-51	75
954	Adaptive designs with arbitrary dependence structure. 2014 , 56, 86-106	7
953	Unbalanced and Partial Group Sequential Methods for Normal Responses in Clinical Trials. 2014 , 33, 7-22	1
952	Randomized, double-blind, placebo-controlled trial of the efficacy and safety of riloncept in the treatment of systemic juvenile idiopathic arthritis. 2014 , 66, 2570-9	114
951	A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned. 2014 , 37, 247-63	11
950	Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. 2014 , 19, 1169-78	50
949	Constraint-induced movement therapy: trial sequential analysis applied to Cochrane collaboration systematic review results. 2014 , 15, 512	4
948	Marker Sequential Test (MaST) design. 2014 , 11, 19-27	37
947	An Ethical Approach to Peeking at Data. 2014 , 9, 293-304	56
946	Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. 2014 , 15, 511-22	58
945	Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor positive advanced breast cancer: CALGB 40302 (Alliance). 2014 , 32, 3353-66	66
944	Early non-invasive ventilation for acute respiratory failure in immunocompromised patients (IVNictus): study protocol for a multicenter randomized controlled trial. 2014 , 15, 372	17
943	Improving efficiency and reducing costs: Design of an adaptive, seamless, and enriched pragmatic efficacy trial of an online asthma management program. 2014 , 38, 19-27	8
942	Consequences of sequential sampling for meta-analysis. 2014 , 46, 1167-83	1
941	Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. 2014 , 15, 305-14	229

940	Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. 2014 , 40, 171-81	85
939	A randomized trial of antibiotic prophylaxis for the prevention of surgical site infection after open mesh-plug hernia repair. 2014 , 207, 476-84	25
938	Group Sequential Tests for Treatment Effect with Covariates Adjustment through Simple Cross-Effect Models. 2014 , 311-319	
937	Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. 2014 , 32, 76-82	132
936	Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: systematic review with meta-analyses of rat models. 2014 , 62, 338-53	94
935	Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 2014 , 370, 23-32	593
934	Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. 2014 , 15, 1442-1450	112
933	Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies. 2014 , 177, 419-438	20
932	Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. 2014 , 58, 1015-22	87
931	Peripheral opioid receptor blockade increases postoperative morphine demands--a randomized, double-blind, placebo-controlled trial. 2014 , 155, 2056-62	42
930	Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. 2014 , 45, 1287-95	96
929	Surgical treatment of moderate ischemic mitral regurgitation. 2014 , 371, 2178-88	269
928	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. 2014 , 371, 213-23	1154
927	Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. 2014 , 32, 458-64	81
926	Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. 2014 , 32, 2735-43	352
925	Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. 2014 , 32, 2440-8	105
924	The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. 2014 , 15, 218	73
923	Interim analysis for binary outcome trials with a long fixed follow-up time and repeated outcome assessments at pre-specified times. 2014 , 3, 323	1

922	Marginal integrity and secondary caries of selectively excavated teeth in vitro. 2014 , 42, 1261-8	27
921	Cost effectiveness of different central venous approaches for port placement and use in adult oncology patients: evidence from a randomized three-arm trial. 2014 , 21, 3725-31	24
920	Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. 2014 , 384, 1265-72	134
919	Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. 2014 , 25, 1152-8	31
918	Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL - III trial). 2014 , 14, 128	14
917	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. 2014 , 371, 906-17	565
916	The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. 2014 , 11, 485-493	54
915	Stroke: prospective evaluation of a prehospital management process based on rescuers under medical direction. 2014 , 32, 438-42	1
914	Effectiveness of the Chaos Falls Clinic in preventing falls and injuries of home-dwelling older adults: a randomised controlled trial. 2014 , 45, 265-71	63
913	Computerized self-interviews improve Chlamydia and gonorrhoea testing among youth in the emergency department. 2014 , 64, 376-84	20
912	Comparable benefit of β -blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. 2014 , 30, 898-903	12
911	Flow diversion versus traditional endovascular coiling therapy: design of the prospective LARGE aneurysm randomized trial. 2014 , 35, 1341-5	20
910	Sequential Tests of Multiple Hypotheses Controlling Type I and II Familywise Error Rates. 2014 , 153, 100-114	16
909	Interim Analysis of Censored Data. 2014 ,	
908	Dose Finding Studies. 2014 ,	
907	Futility Analysis. 2014 , 174-186	2
906	Data and Safety Monitoring. 2014 ,	
905	Alpha-Spending Function. 2014 ,	

904	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. 2014 , 123, 2017-25	93
903	Alpha-Spending Function. 2014 , 53-64	
902	Lan-DeMets Alpha-Spending Function. 2014 ,	
901	The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent. 2014 , 106, 39-47	37
900	Monitoring rules for toxicity in Phase II oncology trials. 2015 , 5, 373-381	4
899	Multiple Comparisons. 2015 , 373-389	
898	Analysis of Variance I. One-Way. 2015 , 391-420	0
897	Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. 2015 , 126, 1294-301	69
896	Neuroprotective potential of erythropoietin in neonates; design of a randomized trial. 2015 , 1, 27	58
895	Self-Harm Intervention: Family Therapy (SHIFT), a study protocol for a randomised controlled trial of family therapy versus treatment as usual for young people seen after a second or subsequent episode of self-harm. 2015 , 16, 501	20
894	Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?. 2015 , 8, 414	4
893	Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring. 2015 , 34, 1117-33	4
892	Alpha, Beta, Meta: Guidelines for Assessing Power and Type I Error in Meta-Analyses. 2015 , 121, 1430-3	44
891	Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. 2015 , 120, 186-192	21
890	Group sequential method for observational data by using generalized estimating equations: application to Vaccine Safety Datalink. 2015 , 64, 319-338	9
889	Data Monitoring Committees Including Operational Issues. 2015 , 1-11	
888	Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning. 2015 , 54, 434-46	1
887	Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). 2015 , 10, e0116965	27

886	Periodontal treatment for preventing adverse pregnancy outcomes: a meta- and trial sequential analysis. 2015 , 10, e0129060	29
885	Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia. 2015 , 10, 2180-2186	1
884	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. 2015 , 386, 444-51	926
883	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. 2015 , 16, 787-94	155
882	Clinical Research. 2015 , 237-274	
881	Adaptive designs for comparative effectiveness research trials. 2015 , 32, 36-44	
880	Stochastically Curtailed Tests Under Fractional Brownian Motion. 2015 , 44, 1053-1064	1
879	The effect of concentrated bone marrow aspirate in operative treatment of fifth metatarsal stress fractures; a double-blind randomized controlled trial. 2015 , 16, 211	12
878	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. 2015 , 3, 1292-8	21
877	Sample Size Re-estimation Designs In Confirmatory Clinical Trials Current State, Statistical Considerations, and Practical Guidance. 2015 , 7, 309-321	18
876	Statistical Methods Used in Interim Monitoring. 2015 , 373-401	1
875	Modifications of sequential designs in bioequivalence trials. 2015 , 14, 180-8	5
874	Brief strategic therapy in first myocardial infarction patients with increased levels of stress: a randomized clinical trial. 2015 , 28, 687-705	10
873	Two-stage designs in bioequivalence trials. 2015 , 71, 271-81	10
872	Allocating recycled significance levels in group sequential procedures for multiple endpoints. 2015 , 57, 90-107	19
871	Protecting the confidentiality of interim data: addressing current challenges. 2015 , 12, 5-11	17
870	Early stopping of RCTs: two potential issues for error statistics. 2015 , 192, 1089-1116	3
869	Outcome of the FUSION vascular graft for above-knee femoropopliteal bypass. 2015 , 61, 713-9.e1	2

868	The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. 2015 , 16, 48	21
867	Clarifying when to recommend progesterone to prevent preterm birth: clear as mud. 2015 , 122, 446-7	
866	Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. 2015 , 3, 692-701	270
865	Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial. 2015 , 47, 529-31	21
864	Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. 2015 , 386, 857-66	590
863	Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. 2015 , 36, 1660-8	234
862	The Influence of Biostatistics at the National Heart, Lung, and Blood Institute. 2015 , 69, 108-120	2
861	Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts. 2015 , 7, 81-94	8
860	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. 2015 , 107,	36
859	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. 2015 , 373, 795-807	1791
858	Randomized Trial of Bicarbonate or Saline Study for the Prevention of Contrast-Induced Nephropathy in Patients with CKD. 2015 , 10, 1519-24	47
857	Efficient Score Statistic in Drug and Vaccine Safety Surveillance. 2015 , 34, 57-76	4
856	Therapeutic hypothermia after out-of-hospital cardiac arrest in children. 2015 , 372, 1898-908	273
855	Multistage adaptive biomarker-directed targeted design for randomized clinical trials. 2015 , 42, 119-31	9
854	Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. 2015 , 33, 1653-9	163
853	Independent data monitoring committees: an update and overview. 2015 , 33, 143-8	10
852	PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. 2015 , 169, 813-822.e3	31
851	A randomized trial of continuous versus interrupted chest compressions in out-of-hospital cardiac arrest: rationale for and design of the Resuscitation Outcomes Consortium Continuous Chest Compressions Trial. 2015 , 169, 334-341.e5	27

850	A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. 2015 , 39, 2776-83	92
849	[Modern study designs and analysis methods in clinical research]. 2015 , 74, 106-12	1
848	Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). 2015 , 36, 1567-74	30
847	Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. 2015 , 33, 332-9	84
846	Sustained Aeration of Infant Lungs (SAIL) trial: study protocol for a randomized controlled trial. 2015 , 16, 95	38
845	Methods for observational post-licensure medical product safety surveillance. 2015 , 24, 177-93	15
844	Two-stage designs for cross-over bioequivalence trials. 2015 , 34, 2403-16	17
843	The Adult Calfactant in Acute Respiratory Distress Syndrome Trial. 2015 , 148, 356-364	48
842	Efficacy outcome selection in the therapeutic hypothermia after pediatric cardiac arrest trials. 2015 , 16, 1-10	26
841	The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. 2015 , 11, 51-9	18
840	Longitudinal clinical trials with adaptive choice of follow-up time. <i>Biometrics</i> , 2015 , 71, 469-77	1.8 3
839	Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. 2015 , 175, 691-700	300
838	Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. 2015 , 100, F216-23	38
837	Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. 2015 , 26, 675-682	37
836	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. 2015 , 385, 1843-52	340
835	Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis. 2015 , 62, 914-22	14
834	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. 2015 , 33, 3788-95	43
833	The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. 2015 , 36, 377-84	178

832	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. 2015 , 373, 1803-13		3725
831	Development of the Serious Illness Care Program: a randomised controlled trial of a palliative care communication intervention. 2015 , 5, e009032		177
830	Design and conduct of a large obstetric or neonatal randomized controlled trial. 2015 , 20, 389-402		14
829	Group Sequential Design for Randomized Phase III Trials under the Weibull Model. 2015 , 25, 1190-205		2
828	Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance. <i>Biometrics</i> , 2015 , 71, 851-8	1.8	21
827	Local anesthetic wound infusion versus standard analgesia in paediatric post-operative pain control. 2015 , 31, 1087-97		11
826	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. 2015 , 7, 36-54		20
825	Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. 2015 , 102, 721-8		165
824	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. 2015 , 386, 1049-56		197
823	Cavity lining after excavating caries lesions: meta-analysis and trial sequential analysis of randomized clinical trials. 2015 , 43, 1291-7		22
822	A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety. 2015 , 12, 189-98		13
821	Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. 2015 , 373, 2225-36		335
820	A review of multiple hypothesis testing in otolaryngology literature. 2015 , 125, 599-603		5
819	Effect of early neonatal vitamin A supplementation on mortality during infancy in Ghana (Neovita): a randomised, double-blind, placebo-controlled trial. 2015 , 385, 1315-23		50
818	Effect of neonatal vitamin A supplementation on mortality in infants in Tanzania (Neovita): a randomised, double-blind, placebo-controlled trial. 2015 , 385, 1324-32		52
817	Effect of intraoperative infiltration with local anesthesia on the development of chronic pain after inguinal hernia repair: a randomized, triple-blinded, placebo-controlled trial. 2015 , 157, 144-54		21
816	Bayesian designs and the control of frequentist characteristics: a practical solution. <i>Biometrics</i> , 2015 , 71, 218-226	1.8	19
815	Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. 2015 , 49, 50-64		18

814	Psychometrics behind Computerized Adaptive Testing. 2015 , 80, 1-20	80
813	The nonverbal environment of self-esteem: Interactive effects of facial-expression and eye-gaze on perceivers' self-evaluations. 2015 , 56, 130-138	11
812	A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. 2015 , 385, 629-639	196
811	A simple and flexible graphical approach for adaptive group-sequential clinical trials. 2016 , 26, 202-16	11
810	Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial. 2016 , 17, 335	10
809	Statistics and Clinical Trials. 2016 , 239-252.e1	
808	Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. 2016 , 65, 273-297	21
807	First-Attempt Intubation Success of Video Laryngoscopy in Patients with Anticipated Difficult Direct Laryngoscopy: A Multicenter Randomized Controlled Trial Comparing the C-MAC D-Blade Versus the GlideScope in a Mixed Provider and Diverse Patient Population. 2016 , 122, 740-750	55
806	Optimal flexible sample size design with robust power. 2016 , 35, 3385-96	7
805	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. 2016 , 16, 1154-1168	103
804	Composite sequential Monte Carlo test for post-market vaccine safety surveillance. 2016 , 35, 1441-53	4
803	Group sequential designs with prospectively planned rules for subpopulation enrichment. 2016 , 35, 3776-91	8
802	A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) Study. 2016 , 49, 181-9	35
801	Blinded Safety Signal Monitoring for the FDA IND Reporting Final Rule. 2016 , 201-211	4
800	An introduction to multiplicity issues in clinical trials: the what, why, when and how. 2017 , 46, 746-755	129
799	Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. 2016 , 17, 309	13
798	Monetary loss surveillance for credit models. 2016 , 35, 347-357	
797	Postdischarge Care of Pediatric Traumatic Brain Injury in Argentina: A Multicenter Randomized Controlled Trial. 2016 , 17, 658-66	6

796	Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials. 2016 , 36, 999-1010	
795	The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. 2016 , 4, e978-e988	149
794	Computation of optimal group sequential designs. 2016 , 35, 453-464	
793	Review of Statistical Innovations in Trials Supporting Vaccine Clinical Development. 2016 , 8, 128-142	5
792	Simultaneous sequential monitoring of efficacy and safety led to masking of effects. 2016 , 76, 155-65	2
791	Different materials for direct pulp capping: systematic review and meta-analysis and trial sequential analysis. 2016 , 20, 1121-32	56
790	Repeated confidence intervals and prediction intervals using stochastic curtailment under fractional Brownian motion. 2016 , 45, 4295-4306	
789	Early tracheostomy in ventilated stroke patients: Study protocol of the international multicentre randomized trial SETPOINT2 (Stroke-related Early Tracheostomy vs. Prolonged Orotracheal Intubation in Neurocritical care Trial 2). 2016 , 11, 368-79	33
788	Inhibition of hybrid layer degradation by cavity pretreatment: Meta- and trial sequential analysis. 2016 , 49, 14-21	24
787	Comparison of a peer facilitated support group to cognitive behavior therapy: Study protocol for a randomized controlled trial for hoarding disorder. 2016 , 50, 98-105	13
786	A nonparametric test for the evaluation of group sequential clinical trials with covariate information. 2016 , 152, 82-99	2
785	Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. 2016 , 30, 1765-1779	144
784	Data Monitoring Committees - Expect the Unexpected. 2016 , 375, 1365-1371	35
783	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 2016 , 375, 1856-1867	2647
782	Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects. 2016 , 58, 1295-1310	0
781	Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial. 2016 , 16, 600-19	45
780	Some Dare Call It Conspiracy: Labeling Something a Conspiracy Theory Does Not Reduce Belief in It. 2016 , 37, 695-705	35
779	A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates. 2016 , 31, 3-19	4

778	Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. 2016 , 16, 173	38
777	Effective Referral of Low-Income Women at Risk for Hereditary Breast and Ovarian Cancer to Genetic Counseling: A Randomized Delayed Intervention Control Trial. 2016 , 106, 1842-8	14
776	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. 2016 , 50, 166-77	39
775	Odds ratio-based group sequential analysis for joint binomial and inverse binomial sampling. 2016 , 35, 207-215	1
774	Using Contour Plots to Assess the Sensitivity of Clinical Trial Design Assumptions. 2016 , 50, 496-509	2
773	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVOC-CTS) trial. 2016 , 103, 42-51	20
772	Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention. 2016 , 5,	34
771	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. 2016 , 10, CD004314	19
770	Statistical issues in study design. 2016 , 103-125	1
769	Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. 2016 , 50, 710-717	8
768	Futility Boundary Design Based on Probability of Clinical Success Under New Drug Development Paradigm. 2016 , 91-105	
767	An ROC Approach to Evaluate Interim Go/No-Go Decision-Making Quality with Application to Futility Stopping in the Clinical Trial Designs. 2016 , 121-147	2
766	Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches. 2016 , 5, 305-12	4
765	Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials. 2016 , 50, 871-881	6
764	Deep brain stimulation for dystonia. 2016 ,	78
763	Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development. 2016 , 15, 96-108	16
762	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLapsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. 2016 , 16, 290	5
761	Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. 2016 , 13, 621-631	20

760	Adaptive designs undertaken in clinical research: a review of registered clinical trials. 2016 , 17, 150	52
759	Evaluating the effectiveness of a family empowerment program on family function and pulmonary function of children with asthma: A randomized control trial. 2016 , 60, 133-44	32
758	Statistical considerations for a trial of Ebola virus disease therapeutics. 2016 , 13, 39-48	23
757	Information time scales for interim analyses of randomized clinical trials. 2016 , 13, 391-9	9
756	Intravenous versus epidural analgesia to reduce the incidence of gastrointestinal complications after elective pancreatoduodenectomy (the PAKMAN trial, DRKS 00007784): study protocol for a randomized controlled trial. 2016 , 17, 194	10
755	Stopping guidelines for an effectiveness trial: what should the protocol specify?. 2016 , 17, 240	16
754	Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. 2016 , 4, 521-535	10
753	Some recommendations for multi-arm multi-stage trials. 2016 , 25, 716-27	49
752	Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. 2016 , 213, 1906-13	34
751	Conduct of Stroke-Related Clinical Trials. 2016 , 1030-1041	2
750	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. 2016 , 375, 2121-2132	480
749	Adaptive Designs for Two Candidate Primary Time-to-Event Endpoints. 2016 , 8, 207-216	6
748	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. 2016 , 172, 160-9	75
747	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. 2016 , 387, 1405-1414	549
746	A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer. 2016 , 155, 295-302	12
745	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. 2016 , 173, 102-7	28
744	Reducing unnecessary measurements in clinical trials with multiple primary endpoints. 2016 , 26, 631-43	2
743	Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. 2016 , 168, 23-29.e4	57

742	A Novel Powerful Joint Analysis with Data Fusion in Two-stage Case-Control Genome-wide Association Studies. 2016 , 45, 2362-2376	
741	Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. 2016 , 16, 580-99	49
740	An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. 2016 , 65, 286-95	58
739	A multi-stage drop-the-losers design for multi-arm clinical trials. 2017 , 26, 508-524	19
738	A Bayesian sequential design using alpha spending function to control type I error. 2017 , 26, 2184-2196	8
737	Group-sequential three-arm noninferiority clinical trial designs. 2017 , 27, 1-24	5
736	More data, less information? Potential for nonmonotonic information growth using GEE. 2017 , 27, 135-147	
735	Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test. 2017 , 9, 35-43	5
734	Stopping rules for long-term clinical trials based on two consecutive rejections of the null hypothesis. 2017 , 46, 1342-1351	1
733	Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children. 2017 , 376, 318-329	159
732	MAGNETIC VT study: a prospective, multicenter, post-market randomized controlled trial comparing VT ablation outcomes using remote magnetic navigation-guided substrate mapping and ablation versus manual approach in a low LVEF population. 2017 , 48, 237-245	10
731	[Trial sequential analysis : Sample size calculation for reliable meta-analyses]. 2017 , 66, 91-99	1
730	Registry-Based Prospective, Active Surveillance of Medical-Device Safety. 2017 , 376, 526-535	44
729	Telemedical support for prehospital Emergency Medical Service (TEMS trial): study protocol for a randomized controlled trial. 2017 , 18, 43	17
728	Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints. 2017 , 59, 703-731	11
727	Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. 2017 , 36, 2067-2080	7
726	Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Midazolam Versus Morphine in Acute Pulmonary Edema": MIMO Trial. 2017 , 31, 209-213	11
725	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. 2017 , 376, 836-847	978

724	Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. 2017, 72, 318-326	35
723	A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. 2017, 34, 429-438	37
722	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. 2017, 5, 399-407	22
721	Bayesian randomized clinical trials: From fixed to adaptive design. 2017, 59, 77-86	22
720	German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. 2017, 28, 1803-1810	17
719	The role of adaptive trial designs in drug development. 2017, 10, 727-736	11
718	Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. 2017, 10, 1189-1198	64
717	Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. 2017, 109,	40
716	Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. 2017, 31, 970-978	9
715	Mortality in caRdIAC surgery (MYRIAD): A randomized controlled trial of volatile anesthetics. Rationale and design. 2017, 59, 38-43	10
714	Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies. 2017, 27, 975-989	2
713	A Bayesian sequential design with binary outcome. 2017, 16, 192-200	7
712	The application of group sequential stopping boundaries to evaluate the treatment effect of an experimental agent across a range of biomarker expression. 2017, 63, 13-18	3
711	Power and sample size estimation for interim analysis using PASS. 2017, 7, 24-28	2
710	Trial Sequential Analysis in systematic reviews with meta-analysis. 2017, 17, 39	430
709	Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. 2017, 31, 2416-2425	18
708	Design and monitoring of multi-arm multi-stage clinical trials. <i>Biometrics</i> , 2017, 73, 1289-1299	1.8 24
707	Bayesian response-adaptive designs for basket trials. <i>Biometrics</i> , 2017, 73, 905-915	1.8 30

706	Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives. 2017 , 45, 375-381	2
705	Proceedings of the University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs?. 2017 , 14, 415-416	1
704	A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. 2017 , 17, 108	21
703	Planning the duration of a survival group sequential trial with a fixed follow-up time for all subjects. 2017 , 46, 7460-7478	
702	Group Sequential Design With Change of Endpoint. 2017 , 9, 338-346	1
701	Living systematic reviews: 3. Statistical methods for updating meta-analyses. 2017 , 91, 38-46	74
700	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. 2017 , 19, 950-957	21
699	Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. 2017 , 266, 470-478	62
698	A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test. 2017 , 16, 451-465	1
697	Considerations on Testing Secondary Endpoints in Group Sequential Design. 2017 , 9, 333-337	1
696	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. 2017 , 6, 461-470	7
695	Relative bioavailability of diazoxide, manufactured at two different international locations, in healthy participants under fasting conditions: an open-label, two-stage, adaptive, sequential two-period crossover study. 2017 , 3,	1
694	Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments. 2017 , 36, 563-580	11
693	Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously. 2017 , 251-275	
692	Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial. 2017 , 2, 13-22	65
691	The United States of America. 2017 , 269-305	1
690	Botulinum toxin type A therapy for cervical dystonia. 2017 , 12, CD003633	34
689	On the Optimal Timing of Futility Interim Analyses. 2017 , 9, 293-301	9

688	Faster online experimentation by eliminating traditional A/A validation. 2017,	2
687	Editorial special invited paper: On the efficient score vector in sequential monitoring. 2017, 36, 435-466	1
686	Computationally Intensive Two-Stage Designs for Clinical Trials. 2017, 1-7	4
685	Increasing efficiency of preclinical research by group sequential designs. 2017, 15, e2001307	25
684	Choice of futility boundaries for group sequential designs with two endpoints. 2017, 17, 119	12
683	Arabin cervical pessary for prevention of preterm birth in cases of twin-to-twin transfusion syndrome treated by fetoscopic LASER coagulation: the PECEP LASER randomised controlled trial. 2017, 17, 256	3
682	GA101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. 2017, 18, 353	4
681	Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. 2017, 18, 387	25
680	Safety of tubal ligation by minilaparotomy provided by clinical officers versus assistant medical officers: study protocol for a noninferiority randomized controlled trial in Tanzanian women. 2017, 18, 499	1
679	Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study. 2017, 7, 79	2
678	Effects of violations of prerequisites in sequential triangular designs. 2017,	
677	Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. 2017, 35, 3160-3168	23
676	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. 2018, 6, 250-254	3
675	Sequential surveillance for drug safety in a regulatory environment. 2018, 27, 707-712	7
674	High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol. 2018, 113, 331-338	54
673	Type I Error Probability Spending for Post-Market Drug and Vaccine Safety Surveillance With Poisson Data. 2018, 20, 739-750	4
672	Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization: The Low-Risk Pulmonary Embolism Prospective Management Study. 2018, 154, 249-256	38
671	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. 2018, 201, 124-135	132

- 670 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. **2018**, 378, 1789-1801 918
- 669 Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes. **2018**, 37, 2187-2207 2
- 668 Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. **2018**, 378, 1313-1322 113
- 667 Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies. **2018**, 29, 573-577 7
- 666 β -Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. **2018**, 30, 930-937 18
- 665 Fluorouracil Filtering Surgery Study One-Year Follow-up. **2018**, 186, xxxiii-xlii 3
- 664 Biostatistical Issues in TBI Clinical Trials. **2018**, 167-185 1
- 663 Topical benzydamine hydrochloride for prevention of postoperative sore throat in adults undergoing tracheal intubation for elective surgery: a systematic review and meta-analysis. **2018**, 73, 889-900 31
- 662 Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). **2018**, 2, CD012693 48
- 661 Significance, Errors, Power, and Sample Size: The Blocking and Tackling of Statistics. **2018**, 126, 691-698 54
- 660 A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs. **2018**, 74, 549-559 5
- 659 A Randomized Controlled Multicenter Trial of an Investigational Liquid Nutritional Formula in Women with Cyclic Breast Pain Associated with Fibrocystic Breast Changes. **2018**, 27, 333-340 4
- 658 Design and Conduct of Clinical Trials for Breast Cancer. **2018**, 362-376.e1
- 657 Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. **2018**, 6, 183-192 29
- 656 The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial. **2018**, 18, 29 20
- 655 Improving outcomes after pediatric cardiac arrest - the ICU-Resuscitation Project: study protocol for a randomized controlled trial. **2018**, 19, 213 9
- 654 Clinical Study Design to Assess Both Short- and Long-term Efficacy in Addition to Group Sequential Test on Safety. **2018**, 52, 690-695
- 653 A group sequential test for treatment effect based on the Fine-Gray model. *Biometrics*, **2018**, 74, 1006-1013 3

652	Step-Down Parametric Procedures for Testing Correlated Endpoints in a Group-Sequential Trial. 2018 , 10, 18-25	7
651	Monitoring Phase II Comparative Clinical Trials with Two Endpoints and Penalty for Adverse Events. 2018 , 20, 719-738	1
650	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. 2018 , 391, 1263-1273	422
649	Controlling alpha for mixed effects models for repeated measures. 2018 , 28, 1055-1077	1
648	Continuously updated network meta-analysis and statistical monitoring for timely decision-making. 2018 , 27, 1312-1330	25
647	Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma. 2018 , 27, 1451-1463	3
646	Sequential designs with small samples: Evaluation and recommendations for normal responses. 2018 , 27, 1115-1127	6
645	Trends in study design and the statistical methods employed in a leading general medicine journal. 2018 , 43, 36-44	9
644	Single-incision surgery trocar-site hernia: an updated systematic review meta-analysis with trial sequential analysis by the Minimally Invasive Surgery Synthesis of Interventions Outcomes Network (MISSION). 2018 , 32, 14-23	30
643	Type I error probability spending for post-market drug and vaccine safety surveillance with binomial data. 2018 , 37, 107-118	11
642	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. 2018 , 15, 89-101	6
641	Utility of a Medical Alert Protection System compared to telephone follow-up only for home-alone elderly presenting to the ED - A randomized controlled trial. 2018 , 36, 594-601	5
640	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. 2018 , 64, 238-242	27
639	Adaptive designs for the one-sample log-rank test. <i>Biometrics</i> , 2018 , 74, 529-537	1.8 8
638	Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. 2018 , 33, 97-102	10
637	Balloon dilation of the eustachian tube for dilatory dysfunction: A randomized controlled trial. 2018 , 128, 1200-1206	70
636	Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. 2018 , 391, 1197-1204	70
635	Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility. 2018 , 52, 459-468	14

634	Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial with Time-to-Event Data: Comparing Group Sequential and Various Adaptive Enrichment Designs. 2018 , 10, 371-404		2
633	A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks. <i>Biometrics</i> , 2018 , 74, 40-48	1.8	13
632	The Effectiveness of Leech Therapy in Chronic Low Back Pain. 2018 , 115, 785-792		9
631	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). 2018 , 36, 2621-2629		39
630	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. 2018 , JCO2018782516		64
629	Trial Termination and Drug Misclassification in Sequential Adaptive Clinical Trials. 2018 , 10, 354-377		3
628	Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216. 2019 , 41, 37-45		6
627	Group sequential clinical trial designs for normally distributed outcome variables.. 2018 , 18, 416-431		
626	Designing one-sided group sequential clinical trials to detect a mixture alternative. 2018 , 37, 268-291		
625	High-intensity versus low-intensity noninvasive positive pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease (HAPPEN): study protocol for a multicenter randomized controlled trial. 2018 , 19, 645		1
624	Methods in the design and implementation of the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial. 2018 , 19, 687		7
623	Statistical Testing of Single and Multiple Endpoint Hypotheses in Group Sequential Clinical Trials. 2018 , 119-149		
622	Power bleaching enhances resin infiltration masking effect of dental fluorosis. A randomized clinical trial. 2018 , 79, 77-84		12
621	Methods for conducting a double-blind randomized controlled clinical trial of three days versus five days of amoxicillin dispersible tablets for chest indrawing childhood pneumonia among children two to 59 months of age in Lilongwe, Malawi: a study protocol. 2018 , 18, 476		8
620	Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early. 2018 , 17, 400-413		4
619	Analysis of Two-Stage Adaptive Trial Designs. 2018 , 217-241		
618	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. 2018 , 202, 97-103		23
617	Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations. 2018 , 159, 1955-1971		28

616	Data and Safety Monitoring. 2018 , 127-140	1
615	Intermediate Topics in Biostatistics. 2018 , 383-409	1
614	The age of blood in pediatric intensive care units (ABC PICU): study protocol for a randomized controlled trial. 2018 , 19, 404	7
613	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session). 2018 , 15, 335-351	4
612	Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. 2018 , 379, 315-326	345
611	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomized controlled trial. 2018 , 19, 160	4
610	Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. 2018 , 11, 641-650	9
609	Sealing or infiltrating proximal carious lesions. 2018 , 74, 15-22	13
608	IntAct: intra-operative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: a randomized controlled trial. 2018 , 20, O226-O234	50
607	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. 2018 , 28, 108-113	20
606	Stochastic optimization of adaptive enrichment designs for two subpopulations. 2018 , 28, 966-982	3
605	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. 2018 , 205, 42-52	27
604	Prognostic Significance of P16 Expression in Penile Squamous Cell Carcinoma: A Meta-Analysis with Trial Sequential Analysis. 2018 , 2018, 8345893	3
603	Design and estimation in clinical trials with subpopulation selection. 2018 , 37, 4335-4352	11
602	Bayesian selective response-adaptive design using the historical control. 2018 , 37, 3709-3722	4
601	Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. 2018 , 378, e34	1232
600	Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance. 2018 , 60, 893-902	2
599	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. 2018 , 378, 2376-2385	127

598	Growth, stool consistency and bone mineral content in healthy term infants fed sn-2-palmitate-enriched starter infant formula: A randomized, double-blind, multicentre clinical trial. 2019 , 38, 1023-1030		25
597	Underestimation of treatment effects in sequentially monitored clinical trials that did not stop early for benefit. 2019 , 28, 3027-3041		6
596	A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data. <i>Biometrics</i> , 2019 , 75, 133-143	1.8	1
595	Optimal group sequential designs constrained on both overall and stage one error rates. 2019 , 48, 4959-4975		
594	Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting. 2019 , 112, 77-86		0
593	Apparently conclusive meta-analyses on interventions in critical care may be inconclusive-a meta-epidemiological study. 2019 , 114, 1-10		5
592	Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints. 2019 , 19, 159		2
591	An additive boundary for group sequential designs with connection to conditional error. 2019 , 38, 4656-4669		2
590	Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass: Randomized Controlled Trial. 2019 , 74, 659-668		21
589	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. 2019 , 381, 432-443		322
588	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. 2019 , 9, e028578		31
587	A variational approach to optimal two-stage designs. 2019 , 38, 4159-4171		9
586	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. 2019 , 7, 699-709		62
585	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 2019 , 6, e616-e629		26
584	Frequency of Screening and SBT Technique Trial - North American Weaning Collaboration (FAST-NAWC): a protocol for a multicenter, factorial randomized trial. 2019 , 20, 587		0
583	A Bayesian Sequential Design for Clinical Trials with Time-to-Event Outcomes. 2019 , 11, 387-397		1
582	The Use of Metaanalysis in Pharmacoepidemiology. 2019 , 897-947		2
581	Prospective approaches to accumulating evidence. 2019 , 547-568		10

580	Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. 2019 , 93, e1474-e1484	23
579	Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation. 2019 , 87, 105874	2
578	Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). 2019 , 20, 601	4
577	The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial. 2019 , 1, 26	8
576	Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. 2019 , 322, 1570-1579	18
575	Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. 2019 , 19, e444-e451	8
574	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. 2019 , 5, 1582-1588	50
573	Effect of a Multicomponent Home-Based Physical Therapy Intervention on Ambulation After Hip Fracture in Older Adults: The CAP Randomized Clinical Trial. 2019 , 322, 946-956	29
572	A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery. 2019 , 381, 1035-1045	40
571	Odds ratio based two-stage group sequential analysis for two-treatment two-period crossover trials. 2019 , 5, 300-313	
570	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. 2019 , 322, 1155-1166	245
569	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. 2019 , 37, 3192-3202	45
568	Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. 2019 , 19, 1181-1190	72
567	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. 2019 , 7, 951-963	71
566	Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial. 2019 , 20, 33	8
565	A sequential density-based empirical likelihood ratio test for treatment effects. 2019 , 38, 2115-2125	3
564	Questionable interim analyses in the Goal-Directed Perfusion Trial study of goal-directed perfusion. 2019 , 157, e277	2
563	Does lumbar drainage reduce postoperative cerebrospinal fluid leak after endoscopic endonasal skull base surgery? A prospective, randomized controlled trial. 2018 , 1-7	48

562	Atraumatic vs conventional restorative treatment for root caries lesions in older patients: Meta-analysis and trial sequential analysis. 2019 , 36, 285-293	7
561	Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer. 2019 , 106, 1147-1155	17
560	Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk. 2019 , 113, 114-122	1
559	Aspirin for Primary Prevention of Cardiovascular Disease. 2019 , 12, e005846	
558	Open versus laparoscopic mesh repair of primary unilateral uncomplicated inguinal hernia: a systematic review with meta-analysis and trial sequential analysis. 2019 , 23, 461-472	39
557	Electronic Alerts for Acute Kidney Injury Amelioration (ELAIA-1): a completely electronic, multicentre, randomised controlled trial: design and rationale. 2019 , 9, e025117	10
556	STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial. 2019 , 6, 2054358119852937	7
555	Farmers Experiments and scientific methodology. 2019 , 9, 1	16
554	Introduction. 2019 , 1-33	
553	Responsibilities of the Data Monitoring Committee and Motivating Illustrations. 2019 , 35-88	
552	Statistical, Philosophical, and Ethical Issues in Data Monitoring. 2019 , 265-334	1
551	Evaluating the effects of switching from cigarette smoking to using a heated tobacco product on health effect indicators in healthy subjects: study protocol for a randomized controlled trial. 2019 , 14, 885-898	11
550	The Role of Expert Judgment in Statistical Inference and Evidence-Based Decision-Making. 2019 , 73, 56-68	29
549	Comparative Safety of Aspiration Thrombectomy Catheters Utilizing Prospective, Active Surveillance of the NCDR CathPCI Registry. 2019 , 12, e004666	1
548	Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). 2019 , 106, 720-728	9
547	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 2019 , 321, 1261-1274	472
546	Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with 'minimally invasive staged segmental artery coil embolisation' (MIS ² ACE): trial protocol for a randomised controlled multicentre trial. 2019 , 9, e025488	19
545	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. 2019 , 37, 589-597	119

544	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. 2019 , 37, 1159-1168	62
543	Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial. 2019 , 39, 5	22
542	Non-invasive Ventilation for early General ward respiratory failure (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan. 2019 , 78, 126-132	2
541	Effectiveness of additional X-ray protection devices in reducing Scattered radiation in radial interventions: protocol of the ESPRESSO randomised trial. 2019 , 9, e029509	1
540	INTERIM ANALYSIS OF CLINICAL TRIALS: SIMULATION STUDIES OF CONDITIONAL POWER UNDER FRACTIONAL BROWNIAN MOTION. 2019 , 27, 1950133	3
539	Deep brain stimulation for dystonia. 2019 , 1, CD012405	23
538	Nonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows. 2019 , 38, 5657-5669	1
537	A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. 2019 , 155, 393-399	12
536	DEBATE-statistical analysis plans for observational studies. 2019 , 19, 233	10
535	Principles and procedures for data and safety monitoring in pragmatic clinical trials. 2019 , 20, 690	6
534	Multiarm, multistage randomized controlled trials with stopping boundaries for efficacy and lack of benefit: An update to nstage. 2019 , 19, 782-802	5
533	Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. 2019 , 25, 254-263	5
532	Sequential Analysis [Further Developments Updated with a Focus on Biomedical, Economic, and Engineering Applications. 2019 , 1-10	
531	Nitroglycerin for treatment of retained placenta: A randomised, placebo-controlled, multicentre, double-blind trial in the UK. 2019 , 16, e1003001	
530	Control of Type I Error Rates in Bayesian Sequential Designs. 2019 , 14,	8
529	Is plaque regrowth inhibited by dentifrice?: A systematic review and meta-analysis with trial sequential analysis. 2019 , 17, 27-38	6
528	Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes. 2019 , 38, 601-612	2
527	Adaptive design in surveys and clinical trials: similarities, differences and opportunities for cross-fertilization. 2019 , 182, 963-982	

526	High-flow versus standard nasal cannula in morbidly obese patients during colonoscopy: A prospective, randomized clinical trial. 2019 , 54, 19-24		37
525	A randomized, controlled, multi-center trial of the efficacy and safety of the Occlutech Figulla Flex-II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects. 2019 , 93, 316-321		14
524	Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial. 2019 , 173, 21-28		37
523	Increased risks for random errors are common in outcomes graded as high certainty of evidence. 2019 , 106, 50-59		31
522	Monitoring fertility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach. 2019 , 61, 488-502		2
521	Medical Biostatistics: Basic Concepts. 2019 , 19-53		0
520	Nonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows. <i>Biometrics</i> , 2019 , 75, 494-505	1.8	1
519	Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer. 2019 , 11, 210-219		
518	Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction. 2019 , 20, 42		4
517	A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III. <i>Biometrics</i> , 2019 , 75, 371-381	1.8	5
516	Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. 2019 , 74, 480-488		0
515	Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence. 2019 , 127, 24-28		9
514	Hierarchical Testing of a Primary and a Secondary Endpoint in a Group Sequential Design With Different Information Times. 2019 , 11, 398-406		13
513	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. 2019 , 393, 253-264		131
512	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. 2019 , 20, 88-99		58
511	Decrease in pregnancy rate after endometrial scratch in women undergoing a first or second in vitro fertilization. A multicenter randomized controlled trial. 2019 , 34, 92-99		20
510	Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study. 2019 , 39, 265-271		5
509	Group sequential BH and its adaptive versions controlling the FDR. 2019 , 199, 219-235		1

508	Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. 2019 , 25, 689-698	5
507	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-Based Randomized Trial: The EFFORT Trial. 2019 , 43, 326-334	21
506	Early Versus Late Initiation of Renal Replacement Therapy in Critically Ill Patients: Systematic Review and Meta-Analysis. 2019 , 34, 714-722	11
505	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. 2020 , 112, 145-153	39
504	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. 2020 , 26, 266-291	3
503	Clinical trials design and conduct. 2020 , 4, 24-37	
502	Group-sequential response-adaptive designs for censored survival outcomes. 2020 , 205, 293-305	
501	Group sequential design for time-to-event data using the concept of proportional time. 2020 , 29, 1867-1890	1
500	Clinical Trial Designs in Oncology. 2020 , 296-307.e2	
499	Sequential monitoring of response-adaptive randomized clinical trials with sample size re-estimation. 2020 , 205, 129-137	0
498	Bayesian Two-Stage Adaptive Design in Bioequivalence. 2019 , 16,	3
497	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. 2020 , 29, 1483-1498	2
496	A Randomized Trial to Evaluate the Effects of Folic Acid and Zinc Supplementation on Male Fertility and Livebirth: Design and Baseline Characteristics. 2020 , 189, 8-26	4
495	USE of group sequential test methods in the survival analysis in aquaculture. 2020 , 515, 734568	1
494	What is the effect of active ingredients in dentifrice on inhibiting the regrowth of overnight plaque? A systematic review. 2020 , 18, 128-141	6
493	Comparison of Bayesian and frequentist group-sequential clinical trial designs. 2020 , 20, 4	15
492	A Bayesian approach to sequential analysis in post-licensure vaccine safety surveillance. 2020 , 19, 291-302	3
491	Statistical inference for the Arrhenius-Weibull accelerated life testing model with imprecision based on the likelihood ratio test. 2020 , 234, 275-289	

490	Sensitivity analyses assessing the impact of early stopping on systematic reviews: Recommendations for interpreting guidelines. 2020 , 11, 287-300	1
489	Some Drawbacks of the Simes Test in the Group Sequential Setting. 2020 , 12, 390-393	2
488	Group sequential design for historical control trials using error spending functions. 2020 , 30, 351-363	
487	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. 2020 , 21, 826	2
486	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. 2020 , 38, 4030-4041 ²⁵	
485	Rationale and methods of the Advanced REperfusion STRategies for Refractory Cardiac Arrest (ARREST) trial. 2020 , 229, 29-39	6
484	Recent advances in clinical trial design considerations in Thera"nostics". 2020 , 96, 106100	1
483	A note on the shape of sample size functions of optimal adaptive two-stage designs. 2020 , 1-8	1
482	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. 2020 , 12, 483-497	22
481	Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. 2020 , 18, 352	19
480	Botulinum toxin type A therapy for cervical dystonia. 2020 , 11, CD003633	7
479	Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide: study protocol for a randomized controlled trial in veterans. 2020 , 21, 924	1
478	Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy. 2020 , 20, 288	3
477	Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint. 2020 , 20, 274	0
476	Overrunning in clinical trials: some thoughts from a methodological review. 2020 , 21, 668	0
475	Comparative analgesic efficacy and safety of intermittent local anaesthetic epidural bolus for labour: a systematic review and meta-analysis. 2020 , 125, 560-579	5
474	Sample sizes in experimental games. 2020 , 74, 221-227	1
473	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. 2020 , 38, 3042-3050	17

472	Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan. 2020 , 64, 1365-1375	22
471	Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation. 2020 , 22, 1480-1486	12
470	Eclipse stemless shoulder prosthesis vs. Univers II shoulder prosthesis: a multicenter, prospective randomized controlled trial. 2020 , 29, 2200-2212	2
469	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. 2020 , 12, 478-482	5
468	Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples. 2020 , 10, e039383	2
467	Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial. 2020 , 3, e2012252	15
466	The effect on consent rates for deceased organ donation in Wales after the introduction of an opt-out system. 2020 , 75, 1146-1152	15
465	Intervention to promote physical activation and improve sleep and response feeding in infants for preventing obesity early in life, the baby-act trial: Rationale and design. 2020 , 99, 106185	2
464	Strategies to Promote Resiliency (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients. 2020 , 10, e037690	6
463	Follicular flushing leads to higher oocyte yield in monofollicular IVF: a randomized controlled trial. 2020 , 35, 2253-2261	17
462	Heparin-bonded versus standard polytetrafluoroethylene arteriovenous grafts: A Bayesian perspective on a randomized controlled trial for comparative effectiveness. 2020 , 168, 1066-1074	2
461	Applications of Adaptive Designs in Generic Drug Development. 2021 , 110, 32-35	
460	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. 2020 , 383, 2345-2357	143
459	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. 2020 , 21, 1917-1930	76
458	Estimation of conditional power for cluster-randomized trials with interval-censored endpoints. <i>Biometrics</i> , 2021 , 77, 970-983	1.8 1
457	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. 2020 , 22, 1780-1788	13
456	References. 2020 , 447-453	
455	Clinical Trial Design-A Review-With Emphasis on Acute Intervertebral Disc Herniation. 2020 , 7, 583	0

454	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. 2021 , 73, 1540-1544	9
453	Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study. 2020 , 12,	0
452	Evaluation of an Adaptive Seamless Design for a Phase II/III Clinical Trial in Recurrent Events Data to Demonstrate Reduction in Number of Acute Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD). 2020 , 12, 273-278	0
451	Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol. 2020 , 10, e038300	5
450	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. 2020 , 126, 3516-3525	21
449	Gastrointestinal Complications After Pancreatoduodenectomy With Epidural vs Patient-Controlled Intravenous Analgesia: A Randomized Clinical Trial. 2020 , 155, e200794	9
448	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. 2020 , 38, 2849-2861	131
447	Optimal alpha spending for sequential analysis with binomial data. 2020 , 82, 1141-1164	2
446	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. 2020 , 21, 528	7
445	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. 2020 , 369, m115	25
444	Information growth for sequential monitoring of clinical trials with a stepped wedge cluster randomized design and unknown intracluster correlation. 2020 , 17, 176-183	1
443	Exact critical values for group sequential designs with small sample sizes. 2020 , 30, 752-764	3
442	Sample size re-estimation for confirmatory two-stage flexible multi-arm trial with normal outcomes. 2020 , 90, 157-178	
441	Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. 2020 , 395, 1195-1207	26
440	Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study. 2020 , 34, 2384-2391	3
439	Impact of Age on tDCS Effects on Pain Threshold and Working Memory: Results of a Proof of Concept Cross-Over Randomized Controlled Study. 2020 , 12, 189	6
438	Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. 2020 , 383, 13-23	30
437	Clinical trials and group sequential testing. 2020 , 565-582	

436	To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. 2020 , 21, 147	14
435	Comparison of alpha-spending plans for near real-time monitoring for Guillain-Barré Syndrome after influenza vaccination during the 2010/11 influenza season. 2020 , 38, 2221-2228	
434	Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial. 2020 , 21, 206	6
433	Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. 2020 , 22, 830-837	7
432	Olaparib for Metastatic Castration-Resistant Prostate Cancer. 2020 , 382, 2091-2102	550
431	A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation. 2020 , 39, 2067-2100	3
430	Strategies in adjusting for multiple comparisons: A primer for pediatric surgeons. 2020 , 55, 1699-1705	13
429	Optimal, two-stage, adaptive enrichment designs for randomized trials, using sparse linear programming. 2020 , 82, 749-772	0
428	Seamless phase 2/3 oncology trial design with flexible sample size determination. 2020 , 39, 2373-2386	1
427	Efficacy of dietary intervention or in combination with exercise on primary prevention of cardiovascular disease: A systematic review. 2020 , 30, 1080-1093	10
426	Effects of simulated sample sizes on the mortality effect estimates in three randomized intensive care unit trials. 2020 , 64, 976-981	
425	Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial. 2020 , 15, e0231241	1
424	The negative self-perceived health of migrants with precarious status in Montreal, Canada: A cross-sectional study. 2020 , 15, e0231327	9
423	Suture fixation versus self-gripping mesh for open inguinal hernia repair: a systematic review with meta-analysis and trial sequential analysis. 2021 , 35, 2480-2492	3
422	A prospective randomized trial comparing liposomal bupivacaine vs standard bupivacaine wound infiltration in open gynecologic surgery on an enhanced recovery pathway. 2021 , 224, 70.e1-70.e11	3
421	Dental plaque score reduction with an oscillating-rotating power toothbrush and a high-frequency sonic power toothbrush: a systematic review and meta-analysis of single-brushing exercises. 2021 , 19, 78-92	3
420	Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to the glo Tobacco Heating Product: A Randomized, Controlled Ambulatory Study. 2021 , 23, 584-591	12
419	BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons.. 2021 , 116, 322-334	2

418	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. 2021 , 101, 106244	
417	Statistically significant but clinically unimportant: a systematic review and meta-analysis of the analgesic benefits of erector spinae plane block following breast cancer surgery. 2021 , 46, 3-12	20
416	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. 2021 , 174, 344-352	36
415	Multiplicity for a group sequential trial with biomarker subpopulations. 2021 , 101, 106249	1
414	A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect. 2021 , 30, 904-915	1
413	The uniform general signed rank test and its design sensitivity. 2021 , 108, 381-396	1
412	Target toxicity design for phase I dose-finding. 2021 , 5, 149-161	
411	Strategies for validating biomarkers using data from a reference set. 2021 , 22, 298-314	1
410	Refined critical boundary with enhanced statistical power for non-directional two-sided tests in group sequential designs with multiple endpoints. 2021 , 62, 1265-1290	3
409	A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. 2021 , 22, 38	1
408	Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies. 2021 , 25, 5	5
407	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. 2021 , 18, e1003454	4
406	Effects of Community-based Exercise Prehabilitation for Patients Scheduled for Colorectal Surgery With High Risk for Postoperative Complications: Results of a Randomized Clinical Trial. 2021 ,	23
405	Physiotherapeutic scoliosis-specific exercises performed immediately after spinal manipulative therapy for the treatment of mild adolescent idiopathic scoliosis: study protocol for a randomized controlled pilot trial. 2021 , 22, 58	1
404	Randomized Controlled Trials 2: Analysis. 2021 , 2249, 213-227	
403	The Bayesian Design of Adaptive Clinical Trials. 2021 , 18,	5
402	Diagnostic Errors Induced by a Wrong a Priori Diagnosis: A Prospective Randomized Simulator-Based Trial. 2021 , 10,	2
401	A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials. 1-10	

400	Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution. 2021 , 20, 610-644	
399	Optimal planning of adaptive two-stage designs. 2021 , 40, 3196-3213	2
398	Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan. 2021 , 65, 834-845	12
397	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. 2021 , 384, 829-841	280
396	Interim analysis of sequential estimation-adjusted urn models with sample size re-estimation. 2021 , 49, 1075	0
395	A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards. 2021 , 20, 879-897	1
394	Dynamic Monitoring of Ongoing Clinical Trials. 1-12	1
393	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. 2021 , 137, 3616-3628	16
392	Feasibility and efficacy of a decision aid for emergency department patients with suspected ureterolithiasis: protocol for an adaptive randomized controlled trial. 2021 , 22, 201	1
391	Stopping for efficacy in single-arm phase II clinical trials. 1-20	
390	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 2021 , 325, 843-854	62
389	Sample size optimization and initial allocation of the significance levels in group sequential trials with multiple endpoints. 2021 ,	3
388	Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs. 2021 , 60, 1-8	1
387	Effectiveness of Standard Local Anesthetic Bupivacaine and Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Truncal Incisions: A Randomized Clinical Trial. 2021 , 4, e210753	3
386	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 2021 , 325, 833-842	54
385	Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. 2021 , 9, 275-284	116
384	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. 2021 , 22, 224	4
383	Improving sample size recalculation in adaptive clinical trials by resampling. 2021 , 20, 1035-1050	

382	Total extraperitoneal (TEP) versus laparoscopic transabdominal preperitoneal (TAPP) hernioplasty: systematic review and trial sequential analysis of randomized controlled trials. 2021 , 25, 1147-1157	9
381	Botulinum toxin type A versus anticholinergics for cervical dystonia. 2021 , 4, CD004312	0
380	A Modified Sequential Probability Ratio Test.. 2021 , 101, 102505-102505	0
379	High-frequency oscillatory ventilation in children: A systematic review and meta-analysis. 2021 , 56, 1872-1888	1
378	Time-uniform, nonparametric, nonasymptotic confidence sequences. 2021 , 49,	9
377	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. 2021 , 6, 271-280	
376	References. 2021 , 503-522	
375	Urgently seeking efficiency and sustainability of clinical trials in global health. 2021 , 9, e681-e690	6
374	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. 2021 , 22, 323	9
373	Effect of alternative income assistance schedules on drug use and drug-related harm: a randomised controlled trial. 2021 , 6, e324-e334	5
372	Clinical outcomes and safety of passive leg raising in out-of-hospital cardiac arrest: a randomized controlled trial. 2021 , 25, 176	0
371	Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis. 2021 , 12, 644260	2
370	Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design. 2021 , 104, 106346	0
369	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. 2021 , 39, 1518-1530	35
368	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. 2021 , 9, 476-486	61
367	Comparison of two devices for automated oxygen control in preterm infants: a randomised crossover trial. 2021 ,	1
366	Group sequential testing for cluster randomized trials with time-to-event endpoint. <i>Biometrics</i> , 2021 ,	1.8
365	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. 2021 ,	11

364	Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data. 2021 , 40, 4890-4913	1
363	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. 2021 , 22, 801-812	35
362	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. 2021 , 22, 813-823	24
361	Randomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia. 2021 , 385, 107-118	26
360	The Perils of Misspecified Priors and Optional Stopping in Multi-Armed Bandits. 2021 , 4, 715690	
359	Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial. 2021 , 16, 2201-2212	8
358	Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial.	3
357	Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial.	2
356	Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect. 1-10	0
355	Group sequential Holm and Hochberg procedures. 2021 , 40, 5333-5350	1
354	Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia. 2021 , 385, 119-129	15
353	Statistical Analysis Plan for the Helmet Non-Invasive Ventilation for COVID-19 Patients (Helmet-COVID) Randomized Controlled Trial.	
352	Trigger Strategy in Repeated Tests on Multiple Hypotheses. 1-8	2
351	Oral Misoprostol alone versus oral misoprostol followed by oxytocin for labour induction in women with hypertension in pregnancy (MOLI): protocol for a randomised controlled trial. 2021 , 21, 537	1
350	Reproducible Hyperparameter Optimization. 1-16	4
349	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. 2021 , 39, 2539-2551	19
348	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). 2021 , 75, 1346-1354	11
347	Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. 2021 , 39, 2938-2947	7

346	Interim monitoring in sequential multiple assignment randomized trials. <i>Biometrics</i> , 2021 ,	1.8	1
345	Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial. 2021 , 6, 329		4
344	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. 2021 , 385, 1196-1206		63
343	Midline incisional hernia prophylaxis using synthetic mesh in an emergency or urgent gastrointestinal tract surgery: a protocol for multicentre randomised clinical trial. 2021 , 11, e045541		0
342	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. 2021 , 27, 2012-2024		53
341	Adaptive Trials in Cardiology: Some Considerations and Examples. 2021 , 37, 1428-1437		
340	Evaluating the efficacy of intranasal oxytocin on pain and function among individuals who experience chronic pain: a protocol for a multisite, placebo-controlled, blinded, sequential, within-subjects crossover trial. 2021 , 11, e055039		0
339	Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. 2021 ,		4
338	Living Systematic Reviews. 2022 , 2345, 121-134		0
337	Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. 2021 , 59, 165-175		1
336	Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial. 2021 , 8, e605-e613		4
335	Interim Analyses During Group Sequential Clinical Trials. 2021 , 326, 1524-1525		1
334	Association of CAT C262T (rs1001179) polymorphism with male infertility: Meta-analysis. 2021 , 30, 100974		
333	Design of Stroke-Related Clinical Trials. 2022 , 944-955.e3		
332	Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. 2021 , 51, 1535-1557		3
331	Antibiotic-Loaded Bone Cement in Prevention of Periprosthetic Joint Infections in Primary Total Knee Arthroplasty: A Register-based Multicentre Randomised Controlled Non-inferiority Trial (ALBA trial). 2021 , 11, e041096		0
330	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. 2021 , 8, 1-88		
329	Sequential Statistical Methods for Prospective Postmarketing Safety Surveillance. 852-867		2

328	Stopping the Randomized Aldactone Evaluation Study Early for Efficacy. 2006 , 148-157	2
327	Stopping the Carotene and Retinol Efficacy Trial: The Viewpoint of the Safety and Endpoint Monitoring Committee. 2006 , 220-227	2
326	Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer. 2006 , 346-359	1
325	Data Safety and Monitoring Boards (DSMBs). 2008 , 151-158	2
324	Adaptive Trial Designs. 2011 , 109-130	1
323	Statistical and Design Considerations for Multiple Sclerosis Clinical Trials. 1996 , 63-103	6
322	Nonparametric Bayesian Group Sequential Design. 1998 , 115-132	1
321	A Simulation Study of a Change-Point Poisson Process Based on Two Well-known Test Statistics. 1995 , 228-238	1
320	A Retrospective of Wald's Sequential Analysis Its Relation to Change-point Detection and Sequential Clinical Trials. 1994 , 19-33	3
319	Adaptive Bayesian Designs for Dose-Ranging Drug Trials. 2002 , 99-181	34
318	Designing, Monitoring, and Analyzing Group Sequential Clinical Trials Using the RCTdesign Package for R. 2013 , 177-208	2
317	Identifying and Addressing Safety Signals in Clinical Trials: Some Issues and Challenges. 2013 , 137-156	4
316	Group Sequential Design of Phase II and III Trials. 2013 , 77-100	1
315	The alpha spending function approach to interim data analyses. 1995 , 75, 1-27	31
314	Timing and Frequency of Interim Analyses in Confirmatory Trials. 2014 , 115-123	2
313	Randomized controlled trials 2: Analysis. 2015 , 1281, 177-90	1
312	Analysis of randomized controlled clinical trials. 2009 , 473, 113-26	2
311	Critical Boundary Refinement in a Group Sequential Trial When the Primary Endpoint Data Accumulate Faster Than the Secondary Endpoint. 2019 , 205-224	2

310	Data Safety and Monitoring Boards (DSMBs). 2014 , 193-202	1
309	Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpoints. 2015 , 235-262	6
308	Group Sequential Methods for Comparing Correlated Receiver Operating Characteristic Curves. 2015 , 89-108	1
307	Adaptive Group Sequential Tests. 2016 , 133-169	1
306	Small sample approach, and statistical and epidemiological aspects. 2011 , 205, 181-202	4
305	Designing Multi-arm Multi-stage Clinical Studies. 2014 , 51-69	6
304	A critical assessment of approaches to improving the efficiency of cancer clinical trials. 1988 , 111, 18-26	1
303	Experimental Design. 2009 , 41-57	1
302	Explaining Growth. 2009 ,	4
301	Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. 1999 , 27, 1409-20	1187
300	SACRAL NEUROMODULATION IN THE TREATMENT OF URGENCY-FREQUENCY SYMPTOMS:. 2000 , 1849-1854	8
299	Evaluating the Efficacy of COVID-19 Vaccines.	1
298	Simple, Defensible Sample Sizes Based on Cost Efficiency. <i>Biometrics</i> , 2008 , 080327002026760-???	1.8 2
297	A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. 1996 , 27, 1453-8	137
296	Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. 1997 , 28, 2347-52	90
295	Aspirin versus heparin in the acute phase of unstable angina.. 1994 , 90, 1107-1107	3
294	Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework. 2019 , 16, 132-141	12
293	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). 2019 , 16, 165-175	30

292	Early Stopping of Cancer Clinical Trials. 2005 , 227-246	2
291	Sample Size Calculation for Survival Data. 2003 , 892-898	3
290	Vaccine Clinical Trials. 2003 , 1005-1022	7
289	MULTI-CENTER CLINICAL TRIALS: RANDOMIZATION AND ANCILLARY STATISTICS. 2008 , 2, 582-600	18
288	Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. 2014 , 9, e108687	72
287	An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. 2015 , 10, e0141104	21
286	Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm ³ . 2000 , 42, 27-36	7
285	The Safety, Tolerability, and Effects on the Systemic Inflammatory Response and Renal Function of the Human Chorionic Gonadotropin Hormone-Derivative EA-230 Following On-Pump Cardiac Surgery (The EASI Study): Protocol for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. 2019 , 8, e114441	5
284	Alpha Spending Function. 2010 , 38-44	1
283	Vaccine Clinical Trials. 2010 , 1402-1415	1
282	PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. 2016 , 20, 1-92	32
281	Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab (the PRIMA trial). 2018 , 22, 1-222	11
280	A pragmatic randomised controlled trial and economic evaluation of family therapy versus treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial. 2018 , 22, 1-222	11
279	4. Sequential Methods for Biomedical Applications. 2003 , 15, 153-167	3
278	Sequential and Flexible Trials. 2021 , 367-391	
277	Multi-arm multi-stage clinical trials for time-to-event outcomes. 2021 , 1-14	0
276	Remote Mobile Outpatient Monitoring in Transplant (Reboot) 2.0: Protocol for a Randomized Controlled Trial. 2021 , 10, e26816	1
275	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. 2021 , 326, 1807-1817	46

274 Frequentist Approaches to Interim Monitoring of Clinical Trials: A Review of Recent Theoretical Developments. **2000**, 21, S87-S124

273 Bayesian Approaches to Interim Monitoring of Clinical Trials: A Review of Recent Theoretical Developments. **2000**, 21, S125-S149

272 ??????????????????????????????. **2001**, 22, 53-65

271 Zwischenauswertungen und statistisches Monitoring der Ergebnisse von klinischen Studien. **2002**, 191-202

270 Planung einer klinischen Studie: Wie viele Patienten sind notwendig?. **2002**, 157-178

269 Human Subjects Research, Ethics, Stopping Rules for Randomized Clinical Trials.

268 Group sequential methods and sample size savings in biomarker-disease association studies. **2003**, 163, 1215-9

7

267 Data Monitoring Committees (DMC). **2003**, 277-287

266 Bayesian Statistics. **2003**, 72-79

265 Group Sequential Methods. **2003**, 423-432

264 Experimental Design in Clinical Trials. **2003**, 311-372

263 Clinical Trials in Neurology. **2004**, 399-424

262 The design of randomized clinical trials in dialysis patients. **2004**, 1521-1542

261 Power and Sample Size for Phase III Clinical Trials of Survival. **2005**, 207-226

260 Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing With an Agonizing Trend. **2006**, 209-219

259 Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease. **2006**, 269-277

258 The Nocturnal Oxygen Therapy Trial Data Monitoring Experience: Problem With Reporting Lags. **2006**, 292-301

257 Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial. **2006**, 360-367

- 256 Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoring Methods. **2006**, 64-72
- 255 Clinical Trials of Herpes Simplex Encephalitis: The Role of the Data Monitoring Committee. **2006**, 285-291
- 254 Sequential Analysis of Quality-of-Life Measurements Using Mixed Rasch Models. **2008**, 333-347
- 253 Zwischenauswertungen und statistisches Monitoring der Ergebnisse von klinischen Studien. **2008**, 207-220
- 252 Biostatistics and Bioinformatics in Clinical Trials. **2008**, 309-326
- 251 Design of Trials for New Therapies in Patients with Rheumatoid Arthritis. **2009**, 387-393 1
- 250 Design and Conduct of Clinical Trials for Breast Cancer. **2009**, 703-713
- 249 Group Sequential Tests Using both Type I and Type II Error Spending Rate Functions on Binomial Response. **2010**, 17, 127-140
- 248 Are red blood cell transfusions associated with nosocomial infections in pediatric intensive care units?. **2010**, 11, 464-8 14
- 247 Clinical Trial Design in Heart Failure. **2010**, 570-593
- 246 An Application of Data-Mining Tool in Fraud Pension Payment Prediction. **2010**, 17, 1-8 1
- 245 Design, Implementation, and Interpretation of Clinical Trials. **2010**, 585-625
- 244 Designing and Conducting Phase III Studies. 1
- 243 Inference Following Sequential Clinical Trials. 1
- 242 Monitoring. 1
- 241 Group Sequential Methods. **2010**, 582-589
- 240 Multiple-stage Designs for Phase II Cancer Trials. **2010**, 872-881
- 239 Data Monitoring Committees (DMC). **2010**, 397-404

- 238 Sample Size Calculation for Survival Data. **2010**, 1200-1205
- 237 Clinical Trials. **2010**, 297-303
- 236 Group Sequential Tests and Variance Heterogeneity in Clinical Trials. **2010**, 590-594
- 235 Bayesian Statistics. **2010**, 122-127
- 234 Interim Analysis. **2010**, 654-658
- 233 Further Topics. **2010**,
- 232 Adaptive Interim Analyses in Clinical Trials. **2010**, 8-1-8-13
- 231 From Group Sequential to Adaptive Designs. **2010**, 5-1-5-25
- 230 Adaptive Trial Simulation. **2010**, 24-1-24-18
- 229 Efficiency of Adaptive Designs. **2010**, 25-1-25-16
- 228 Good Practices for Adaptive Clinical Trials. **2010**, 27-1-27-12
- 227 Phase III Clinical Trials with Anticancer Agents. **2011**, 163-188
- 226 Meta-Analysis of Clinical Trials. **2010**, 221-246
- 225 Bibliography. 404-427
- 224 Biostatistique : plans expérimentaux. **2011**, 957-972
- 223 Adaptive Trial Design. **2011**, 87-115
- 222 References. **2011**, 553-576
- 221 Sequential Designs for Clinical Trials. **2012**, 57-79

220 Regulatory Perspectives - A Review of FDA Draft Guidance. **2011**, 313-328

219 Analysis of Sequential Clinical Trials. **2012**, 81-125

218 References. 311-327

217 Statistics and Clinical Trials. **2012**, 223-237

216 References. 307-316

215 Introduction. **2013**, 1-10

1

214 Time-Sequential Design of Clinical Trials with Failure-Time Endpoints. **2013**, 123-152

213 Nonlinear Regression, Experimental Design, and Phase I Clinical Trials. **2013**, 11-35

212 Bayesian Statistics. **2012**, 122-127

211 Clinical Trials. **2012**, 297-303

210 Sample Size Calculation for Survival Data. **2012**, 1200-1205

209 Group Sequential Methods. **2012**, 582-589

208 Vaccine Clinical Trials. **2012**, 1402-1415

207 Alpha Spending Function. **2012**, 38-44

206 On the Use of Local Assessments for Monitoring Centrally Reviewed Endpoints with Missing Data in Clinical Trials. **2013**, 3, 41-54

205 References. 248-256

204 Sample Size in Approximate Sequential Designs Under Several Violations of Prerequisites. **2014**, 401-408

203 The Need for and the Future of Adaptive Designs in Clinical Development. **2014**, 3-23

- 202 Recent Developments in Group-Sequential Designs. **2014**, 97-118
- 201 Alternativen Sequentieller Auswertungsverfahren bei Therapiestudien. **1981**, 277-288
- 200 Methodische Probleme bei Langzeitstudien; insbesondere das Problem des Therapie-Abbruchs. **1981**, 136-146
- 199 Strategien zum Abbruch von Kontrollierten Therapiestudien [Probleme und Gegenwärtig Diskutierte Ansätze. **1981**, 580-588 1
- 198 Biostatistical considerations for head and neck cancer research. **1984**, 473-502
- 197 Procedures for Serial Testing in Censored Survival Data. **1984**, 124-138
- 196 Sequentielle Versuchspläne Bei Klinischen Experimenten. **1984**, 73-93
- 195 Combining Evidence from Multiple Studies. **1988**, 221-226
- 194 Statistical properties and use of sequential methods in randomized clinical trials when the response criterion is censored. **1988**, 111, 207-15
- 193 Dilemmas in Sepsis Clinical Trials Design and Analysis. **1992**, 289-307
- 192 Statistical methods for early breast cancer trials. **1992**, 60, 27-53
- 191 Multicenter Trials: Design and Conduct. **1994**, 167-181 0
- 190 The Monitoring and Reporting of Clinical Trials. **1995**, 354-369
- 189 At the Interface of Statistics and Medicine: Conflicting Paradigms. **1997**, 107-134
- 188 Group Sequential Design with Delayed Observations for Selecting One of Two Processes in a Production System. **1997**, 168-182
- 187 Literatur. **1998**, 101-111
- 186 Monitoring Response Variables. **1998**, 246-283
- 185 Statistical Methods in Small Animal Experimentation. **1998**, 47-54

184 Interim Analyses: Tussentijds Statistisch Toetsen. **1999**, 121-128

183 Basic Biostatistical Methods in Oncology: Principles of Clinical Research Methods. **1999**, 1186-1201

182 References. 213-225

181 Further Developments. **2015**, 69-74

180 Repeated Significance Tests. **2016**, 3-23

179 Introduction. **2016**, 1-14

178 Interim Evaluation of Efficacy or Futility in Clinical Trials with Two Co-primary Endpoints. **2016**, 51-65

177 Group-Sequential Three-Arm Non-inferiority Clinical Trials. **2016**, 81-95

176 Procedures with Equally Sized Stages. **2016**, 25-62

175 Sample Size Recalculation in Clinical Trials with Two Co-primary Endpoints. **2016**, 41-49

174 Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints. **2016**, 67-80

173 Interim Evaluation of Efficacy in Clinical Trials with Two Co-primary Endpoints. **2016**, 15-39

172 Design, Implementation, and Interpretation of Clinical Trials. **2016**, 601-635

171 Data and Analysis Considerations in Oncology Clinical Trials. **2016**, 4,

170 Interim Monitoring. **2017**, 189-196

o

169 Group-Sequential and Adaptive Designs. **2017**, 53-63

168 5. Bayesian Adaptive Designs. **2017**, 157-176

167 Interim Analyses: Design and Analysis Considerations for Survival Trials When Hazards May Be Nonproportional. **2018**, 347-376

- 166 Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures. **2018**, 235-267
- 165 Considerations for the design of vaccine efficacy trials during public health emergencies. 0
- 164 A PROSPECTIVE OBSERVATIONAL STUDY OF MANAGEMENT PROTOCOL OF LOCALLY ADVANCED CARCINOMA RECTUM AT MGMMC AND MY HOSPITAL, INDORE. **2018**, 7, 2628-2633
- 163 Methodological Foundations of Clinical Research. **2019**, 49-85
- 162 Decision-Making in Sequential Adaptive Clinical Trials, with Implications for Drug Misclassification and Resource Allocation. **2020**, 321-345 0
- 161 Glyceryl trinitrate to reduce the need for manual removal of retained placenta following vaginal delivery: the GOT-IT RCT. **2019**, 23, 1-72 12
- 160 Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial.
- 159 Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study. **2020**, 24, 1-152 0
- 158 The performance of the log rank test for different relationships between the hazards: the case of the triangular test in comparison with some other sequential tests. 1-24
- 157 Protocol Design for Sudden Death Prevention. **1983**, 122-129
- 156 Essential statistical principles of clinical trials of pain treatments. **2021**, 6, e863 3
- 155 Remote Mobile Outpatient Monitoring in Transplant (Reboot) 2.0: Protocol for a Randomized Controlled Trial (Preprint).
- 154 Glue versus mechanical mesh fixation in laparoscopic inguinal hernia repair: meta-analysis and trial sequential analysis of randomized clinical trials. **2021**, 108, 14-23 2
- 153 Análisis interino de un ensayo clínico aleatorizado sobre contacto piel a piel temprano versus inmediato en recién nacidos de término. **2020**, 87, 126-131 1
- 152 Group sequential designs applied in psychological research. **2020**, 16, 75-91 1
- 151 Complementary hypotheses in safety surveillance. **2020**, 39, 417-430
- 150 Sequential design and analysis in the randomized clinical trial: A historical perspective. **2020**, 39, 295-306
- 149 Here, There be dragons□**2006**, 1-31

148 Group Sequential Analysis Procedures. **2006**, 113-142

147 Bayesian Statistical Monitoring. **2006**, 201-220

146 Klinische Studien: Planung, Durchführung und Interpretation. **2006**, 634-644

145 SCPRT: A Sequential Procedure That Gives Another Reason to Stop Clinical Trials Early. **2007**, 419-434

144 Zwischenauswertungen und statistisches Monitoring der Ergebnisse von klinischen Studien. **2007**, 207-220

143 Model Futility and Dynamic Boundaries with Application in Banking Default Risk Modeling. **2007**, 163-174

142 An iterative method to protect the type I error rate in bioequivalence studies under two-stage adaptive $2\bar{0}$ crossover designs. **2021**, 63, 122-133 0

141 Targeted design for adaptive clinical trials via semiparametric model. **2020**, 17, 177-190 1

140 Impact of early surveillance on safety signal identification in the CathPCI DELTA study.. **2020**, 2, e000047

139 Futility Designs. **2021**, 1-16

138 The impact of Geriatric Emergency Department Innovations (GEDI) on health services use, health related quality of life, and costs: Protocol for a randomized controlled trial. **2020**, 97, 106125 1

137 On asymptotic normality in estimation after a group sequential trial. **2020**, 39, 443-466

136 Interim Analysis in Clinical Trials. **2021**, 1-20

135 Rationale and Design of a Cluster-Randomized Pragmatic Trial Aimed at Improving Use of Guideline Directed Medical Therapy in Outpatients with Heart Failure: PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF). **2021**, 244, 107-107 2

134 Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. **2021**, 11, e053684 2

133 Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. **2021**, 385, 2123-2131 23

132 Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. **2021**, 272989X211045036 0

131 Adaptive Designs. **2021**, 225-251

130	Statistical analysis plan for the Dual mTorC Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).. 2022 , 23, 13	0
129	Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults.. 2022 ,	18
128	Accelerated versus watchful waiting strategy of kidney replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomized clinical trials.. 2022 , 15, 974-984	0
127	Evaluating the association of TRPA1 gene polymorphisms with pain sensitivity: a protocol for an adaptive recall by genotype study.. 2022 , 15, 9	1
126	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534.. 2022 , 29, 3252	0
125	An order restricted multi-arm multi-stage clinical trial design.. 2022 ,	0
124	Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial.. 2022 , 23, 105	1
123	The Effect of Video Education on Skin-to-Skin Contact at the Time of Delivery: A Randomized Controlled Trial.. 2022 , 12, e10-e16	0
122	Methoden klinischer Prüfung in der Onkologie. 2021 , 1-53	
121	Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.. 2022 ,	124
120	Interpretation of Map Symbols in the Context of Gamers' Age and Experience. 2022 , 11, 150	4
119	Data and Safety Monitoring Board Monitoring of Clinical Trials for Early Efficacy. 2022 , 1,	2
118	Early versus delayed defunctioning ileostomy closure after low anterior resection for rectal cancer: a meta-analysis and trial sequential analysis of safety and functional outcomes.. 2022 ,	2
117	Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest.. 2022 , 386, 724-734	2
116	Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.. 2022 , 22, 50	0
115	Futility Analysis. 1-9	
114	Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?. 2022 , 68, 1982-2002	0
113	Efficiency in sequential testing: Comparing the sequential probability ratio test and the sequential Bayes factor test.. 2022 , 1	

112	Group sequential design for randomized trials using "first hitting time" model.. 2022,	0
111	A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta.. 2022, 11,	1
110	The Effectiveness of a Standardized Ice-Sheet Cooling Method Following Exertional Hyperthermia.. 2022,	0
109	A note on familywise error rate for a primary and secondary endpoint.. <i>Biometrics</i> , 2022,	1.8
108	AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery.. 2022, 12, e051144	1
107	Associations of statin use with the onset and progression of open-angle glaucoma: A systematic review and meta-analysis.. 2022, 46, 101364	0
106	Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.. 2022,	2
105	Group sequential designs for in vivo studies: Minimizing animal numbers and handling uncertainty in power analysis.. 2022, 145, 248-254	
104	Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. 2021,	3
103	Bland-Altman Limits of Agreement from a Bayesian and Frequentist Perspective. 2021, 4, 1080-1090	
102	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. 2021,	0
101	A simulation-based comparison of estimation methods for adaptive and classical group sequential clinical trials.. 2021,	1
100	Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.. 2022, 22, 118	0
99	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.. 2022, JCO2101942	1
98	Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.. 2022, 5, e227852	3
97	Optimization of adaptive designs with respect to a performance score.. 2022,	
96	Fundamentals of Biostatistics. 28-41	
95	Bias and Random Error. 42-51	

94	Efficacy of an oscillating-rotating power toothbrush compared to a high-frequency sonic power toothbrush on parameters of dental plaque and gingival inflammation.. 2022,	0
93	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.. 2022,	21
92	Effect of Early vs Standard Approach to Tracheostomy on Functional Outcome at 6 Months Among Patients With Severe Stroke Receiving Mechanical Ventilation: The SETPOINT2 Randomized Clinical Trial.. 2022,	6
91	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. 2006, 11, 751-760	9
90	Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz. 2005, 10, 171-177	22
89	Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial.. 2022, 12, e056713	0
88	Two-stage designs with small sample sizes. 1-7	
87	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FITNESS (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. 2022, 12, e056147	0
86	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.	6
85	Surgical versus non-surgical treatment of humeral SHAFT fractures compared by a patient-reported outcome: the Scandinavian Humeral diAphyseal Fracture Trial (SHAFT) study protocol for a pragmatic randomized controlled trial. 2022, 23,	0
84	A MULTICENTER RANDOMIZED CONTROLLED TRIAL OF SURVEILLANCE VERSUS ENDOSCOPIC THERAPY FOR BARRETT'S ESOPHAGUS WITH LOW-GRADE DYSPLASIA: THE SURVENT TRIAL STUDY RATIONALE, METHODOLOGY, INNOVATION AND IMPLICATIONS. 2022,	1
83	Optimal Weighted Multiple-Testing Procedure for Clinical Trials. 2022, 10, 1996	
82	PrEggNut Study: protocol for a randomised controlled trial investigating the effect of a maternal diet rich in eggs and peanuts from <23 weeks gestation during pregnancy to 4 months lactation on infant IgE-mediated egg and peanut allergy outcomes. 2022, 12, e056925	0
81	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. 2022,	9
80	Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation. 2022, 327, 2296	9
79	Early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trial. 2022, 12, e061953	0
78	Group sequential methods for the Mann-Whitney parameter. 096228022211071	
77	Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials. 1-16	

76	Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q ¶IMPROVE CODEL: the NOA-18 trial. 2022 , 22,	0
75	Onlay and retrorectus synthetic nonabsorbable mesh-augmented fascia closure during midline laparotomy: A systematic review and updated meta-analysis using trial sequential analysis. 2022 , 44, 100501	
74	Different Approaches to requesting Consent for Routine data linkage in Neonatal follow-up (ACORN): protocol for a 2¶ factorial randomised trial. 2022 , 12, e060476	
73	Trial of Erythropoietin for Hypoxic¶chemic Encephalopathy in Newborns. 2022 , 387, 148-159	5
72	The design and analysis of vaccine trials for COVID -19 for the purpose of estimating efficacy. 2022 , 21, 790-807	1
71	Perioperative Hemodynamic Optimization in Patients at Risk for Delirium ¶A Randomized-Controlled Trial. 9,	
70	Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).	0
69	Asymptotically optimal multistage tests for iid data. 2022 ,	
68	An alternative to traditional sample size determination for small patient populations. 1-27	
67	Backward Sequential Significance Testing in Survival Trials. 1-13	
66	A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs.	
65	A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019.	
64	Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. 2022 , 27, 917-927	0
63	Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.	0
62	Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).	3
61	Comparison of treatments with ordinal responses in trials with sequential monitoring and response-adaptive randomization.	
60	Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH). 2022 , 22,	
59	Bayesian and frequentist approaches to sequential monitoring for fertility in oncology basket trials: A comparison of Simon¶ two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. 2022 , 17, e0272367	

- 58 The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial. **2022**, 23,
- 57 Informed Bayesian survival analysis. **2022**, 22, ○
- 56 Intravenous amino acid therapy for kidney protection in cardiac surgery a protocol for a multi-Centre randomized blinded placebo controlled clinical trial. The PROTECTION trial. **2022**, 121, 106898 ○
- 55 Interim Analysis in Clinical Trials. **2022**, 1083-1102 ○
- 54 Futility Designs. **2022**, 1067-1082 ○
- 53 Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. 174077452211183 ○
- 52 Impact of immediate and continuous heart rate feedback by dry electrode ECG on time to initiation of ventilation after birth: protocol for a randomised controlled trial. **2022**, 12, e061839 ○
- 51 Group sequential methods for interim monitoring of randomized clinical trials with time-lagged outcome. ○
- 50 Mechanical bowel preparation with or without oral antibiotics for rectal resection for cancer (REPCA trial): a study protocol for a multicenter randomized controlled trial. ○
- 49 Improving the statistical power of economic experiments using adaptive designs. 1
- 48 Estimation of the treatment effect following a clinical trial that stopped early for benefit. 096228022211224 ○
- 47 A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy. **2022**, 3, e198 ○
- 46 Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis. 16, ○
- 45 Bounded-width confidence interval following optimal sequential analysis of adverse events with binary data. 096228022211223 ○
- 44 Online control of the False Discovery Rate in group-sequential platform trials. 096228022211290 ○
- 43 Ending Clinical Trials Prematurely. **2022**, 261-272 ○
- 42 Impact of a package of health, nutrition, psychosocial support, and WaSH interventions delivered during preconception, pregnancy, and early childhood periods on birth outcomes and on linear growth at 24 months of age: factorial, individually randomised controlled trial. e072046 1
- 41 Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. **2022**, 1

40	INTERPRETATION AND ESTIMATION OF CONDITIONAL POWER IN INTERIM ANALYSES OF CLINICAL TRIALS: OFTEN IGNORED IN DECISION MAKING PROCESS. 2022 , 51-55	0
39	Replacing Protein via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients: A Multicenter Randomized Controlled Trial: The REPLENISH Trial Protocol.	0
38	Effect of personalized perioperative blood pressure management on postoperative complications and mortality in high-risk patients having major abdominal surgery: protocol for a multicenter randomized trial (IMPROVE-multi). 2022 , 23,	0
37	Point estimation following a two-stage group sequential trial. 096228022211377	0
36	A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019.	2
35	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma.	7
34	Vaginal Cleansing Before Unscheduled Cesarean Delivery to Reduce Infection: A Randomized Clinical Trial. 2022 ,	0
33	Genecriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial. 2022 ,	0
32	Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial.	0
31	The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from Myeloma XI a multicentre, open-label, randomised, phase III trial.	0
30	Hypertonic saline infusion does not improve the chance of primary fascial closure after damage control laparotomy: a randomized controlled trial. 2023 , 18,	0
29	Resin Infiltration of Non-Cavitated Proximal Caries Lesions in Primary and Permanent Teeth: A Systematic Review and Scenario Analysis of Randomized Controlled Trials. 2023 , 12, 727	0
28	Further Studies are Needed for Testing the Effects of Topical Conditioned Medium of Stem Cells in Facial Skin Nonsurgical Resurfacing Modalities for Antiaging.	0
27	A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in naïve patients with positive mpMRI.	0
26	References. 2023 , 383-393	0
25	High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.	0
24	2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. 2023 ,	0
23	Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.	0

- 22 The outcomes of combined endoscopic surgery and fibrinolytic treatment protocol for intraventricular hemorrhage: a randomized controlled trial. **2023**, ○
- 21 On Bayesian Sequential Clinical Trial Designs. **2023**, 1-16 ○
- 20 Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. **2023**, 388, 489-498 6
- 19 Monitoring Participant Safety in Phase I and II Interventional Trials: Options and Controversies. **2004**, 52, 446-452 ○
- 18 Point estimation for adaptive trial designs II : Practical considerations and guidance. ○
- 17 Randomized clinical trial: Long-term Staphylococcus aureus decolonization in patients on home parenteral nutrition. **2023**, 42, 706-716 ○
- 16 Sequential sampling in prospective observational studies. **2023**, 17, ○
- 15 Adaptive clinical trials and master protocols. **2023**, 313-323 ○
- 14 Sample Size Calculation. **2023**, 339-419 ○
- 13 Scandinavian trial of Uncomplicated Aortic Dissection Therapy: study protocol for a randomized controlled trial. ○
- 12 Bayesian sample size planning for developmental studies. ○
- 11 Interim monitoring of sequential multiple assignment randomized trials using partial information. ○
- 10 Importance of sequential methods in meta-analysis: implications for postoperative mortality, delirium, and stroke management. **2023**, 130, 395-401 ○
- 9 The Cognitive Skills in Interpretation of Spatial Situations in the League of Legends game. 104687812311656 ○
- 8 Scandinavian trial of uncomplicated aortic dissection therapy: study protocol for a randomized controlled trial. **2023**, 24, ○
- 7 Statistical methods for seamless phase II/III design. **2022**, 43, 37-62 ○
- 6 Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. ○
- 5 Incorporating efficacy data from initial trials into subsequent evaluations of vaccines against respiratory syncytial virus. ○

- 4 Power Calculations and Critical Values for Two-Stage Nonparametric Testing Regimes. **2023**, 409-428 ○
- 3 Building a Foundation for More Flexible A/B Testing: Applications of Interim Monitoring to Large Scale Data. **2023**, 1-16 ○
- 2 When we shouldn't borrow information from an existing network of trials for planning a new trial. 14, ○
- 1 Fully order restricted multi-arm multi-stage clinical trial design. ○